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The BreastScreen Australia monitoring report 2012–2013 presents the latest 
national statistics in the monitoring of BreastScreen Australia, which aims 
to reduce illness and death resulting from breast cancer through organised 
screening to detect cases of unsuspected breast cancer in women, thus 
enabling early intervention. Around 54% of women in the target age 
group 50–69 took part in the program, with more than 1.4 million women 
screening in 2012–2013.
Breast cancer mortality is at a historic low, at 42 deaths per 100,000 women. 
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Summary 
BreastScreen Australia is the national breast cancer screening program. It aims to reduce 
illness and death from breast cancer through an organised approach to the early detection of 
breast cancer, using screening mammography to detect unsuspected breast cancer in women. 
Detection at an early stage provides an opportunity for early treatment, which can reduce 
illness and death. Women aged 40 and over are eligible for free mammograms every 2 years. 
This report is the latest in the BreastScreen Australia monitoring report series, which is 
published annually to provide regular monitoring of national participation and performance 
of BreastScreen Australia. The report presents preliminary participation data for 2013–2014 
and final data for 2012–2013, as well as the latest available data on incidence and mortality.  
As part of the 2013–14 Federal Budget, the Australian Government committed $55.7 million 
over 4 years to expand BreastScreen Australia’s target age range from 50–69 to 50–74 from  
1 July 2013. However, most data in 2012–2013 were collected when only women aged 50–69 
were actively targeted, which makes it the appropriate target age group for this report.  
The following statistics refer to the latest data available for women aged 50–69. 
Breast cancer is the most common cancer diagnosed in Australian women 
In 2011, there were 7,499 new cases of invasive breast cancer diagnosed in Australian women 
aged 50–69. This is equivalent to just under 300 new cases per 100,000 women, and makes 
breast cancer the most common cancer affecting Australian women. 
Incidence has remained steady at around 300 per 100,000 women for over a decade.  
In 2012, 1,126 women aged 50–69 died from breast cancer, which is equivalent to 44 deaths 
per 100,000 women. This makes breast cancer the second-most common cause of 
cancer-related death for Australian women.  
Breast cancer mortality fell from 68 deaths per 100,000 women in the target age range in 1991 
(when BreastScreen Australia began) to 42 per 100,000 women in 2012 (age-standardised). 
Incidence of breast cancer was lower for Indigenous women than for non-Indigenous women 
at 203 compared with 271 new cases per 100,000 women, but mortality from breast cancer 
was higher at 48 compared with 44 deaths per 100,000 women (all rates age-standardised). 
More than half of targeted women participate in BreastScreen Australia 
In both 2012–2013 and 2013–2014, more than 1.4 million women aged 50–69 had a screening 
mammogram through BreastScreen Australia, which is around 55% participation. 
Participation of Aboriginal and Torres Strait Islander women was lower at 36% in 2012–2013.  
Participation has been 54% or 55% for all years between 2010–2011 and 2013–2014. 
Some women are recalled for further investigation 
In 2013, 12% of women screening for the first time and 4% of women attending subsequent 
screens were recalled for further investigation. These rates are slightly higher than for 2012. 
More than half the cancers detected by BreastScreen Australia are small 
Small breast cancers (≤15 mm in diameter) tend to be associated with more treatment options 
and improved survival. In 2013, a high proportion of invasive breast cancers detected were 
small: 46% of invasive breast cancers detected in those attending their first screen, and 61% 
in those attending subsequent screens. These are similar to the figures for 2012.
 viii 
Report card 
 Latest data Previous data Recent trend (last 3–5 years) 
Participation 53.7% in 2013–2014 
(preliminary) 
54.4% in 2012–2013  
(final)  
54.6% 
 
54.8% 
Continuing trend with  
slight fall from 55% to 54% 
 
Rescreening 
After first screening round  
After second screening round  
After subsequent screening rounds 
 
59.6% 
67.8% 
81.6% 
 
58.3% 
67.8% 
82.8% 
 
Steady at just under 60% 
Steady at around 68% 
 Steady at around 82% 
 
Women recalled for further investigation  
First screening round 
Subsequent screening rounds 
 
11.6% 
3.9% 
 
10.8% 
3.4% 
Continuing trend with  
slight rise from 11% to 12% 
Steady at around 4% 
 
Detection of invasive breast cancer 
First screening round 
Subsequent screening rounds 
Small breast cancer detection 
 
107.9 
47.6 
30.4 
 
103.6 
43.9 
28.2 
 
Rising from 80 to 108 
Rising from 44 to 48 
Steady at around 30 
 
Detection of DCIS 
First screening round 
Subsequent screening rounds 
 
29.2 
12.8 
 
22.8 
11.0 
 
Rising from 20 to 29 
Rising from 12 to 13 
 
Incidence in 2011 292.8 301.2 Steady at around 300  
Mortality in 2012 42.4 44.0 Falling from 47 to 42  
Report card uses age-standardised rates where available to aid in comparison of trends. All data shown are for women aged 50–69. ‘Previous data’ refers to the previous calendar year except for participation which is 
measured over 2 calendar years, and for which ‘previous data’ refers to the previous non-overlapping 2-year period (for instance, if ‘latest data’ refers to 2013–2014, then ‘previous data’ refers to 2011–2012).  
Data for detection of invasive breast cancer and ductal carcinoma in situ (DCIS) are ‘per 10,000 women screened’; data for incidence and mortality are ‘per 100,000 women in the population’. 
Green light: positive trend—all is well. Amber light: trend slipping in an unfavourable direction—keep an eye on this. Red light: 
unfavourable trend—may be cause for concern/require further investigation or monitoring. 
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Navigating changes in this report 
Regular users of this annual monitoring report will notice that the BreastScreen Australia monitoring report 2012–2013 looks a little different to 
the previous report BreastScreen Australia monitoring report 2011–2012. The same data are presented, along with much of the same supporting 
information, but the structure and format have changed. Therefore this ‘map’ has been provided to aid regular users in the navigation of this 
report to ensure they are still able to find the data and information they require. 
Where are all the data tables? 
All the data tables that were previously interspersed amongst the 
text of each performance indicator chapter now appear together in  
Appendix A. These tables appear in the same order, and are  
numbered according to the performance indicator (for example, 
participation data tables, being indicator 1, are numbered from  
A1.1 to A1.8, and rescreening tables are numbered from A2.1 to  
A2.3), so that regular users can still access the detailed data as  
usual.  
Why are fewer data being reported? 
Regular users will also notice that the sections that report on data are shorter and described differently. Whereas there used to be a chapter 
for each performance indicator, with every result for every disaggregation reported, only selected results appear in this report, with a focus 
on the most important findings—the ‘story’ of what occurred in BreastSreen Australia in 2012–2013. Further, data from different 
performance indicators have been incorporated into a single chapter so that data can be discussed in context, rather than isolation. This 
means that participation and rescreening data are reported together in a chapter called Screening behaviour, interval cancer and program 
sensitivity data are reported together in a section called Sensitivity of the screening test, and recall to assessment, breast cancer detection and 
DCIS detection data are reported in a section called Detection of breast cancer and ductal carcinoma in situ (DCIS). The overall aim of these 
changes is to have key information easy to find while removing any repetition or redundancy in the text that might mask key findings. 
Note that the fact that some data are not reported does not imply these are not important to monitor; all data are analysed and monitored. 
Where has the information from the introduction gone? 
The introductory section is now much shorter, but key information has been retained and, rather than appearing at the beginning of the 
report, is now dispersed within the relevant sections of the text, glossary and appendixes. 
Indicator … Appendix A 
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1 Introduction 
1.1 Breast cancer 
Cancer is a group of several hundred diseases in which abnormal cells are not destroyed 
naturally by the body but instead multiply and spread out of control. Cancers are 
distinguished from each other by the specific type of cell involved and the place in the body 
in which the disease began.  
Breast cancer most commonly originates in the ducts of the breast (which carry milk from the 
lobules to the nipple) but can also originate in the lobules (small lobes of the breast that 
produce milk). More rarely, breast cancer can originate in the connective tissue of the breast. 
The arrangement of breast tissue is illustrated in Figure 1.1. 
 
Source: National Cancer Institute 2007 (<http://visualsonline.cancer.gov>). 
Figure 1.1: Anatomy: The breast and adjacent lymph nodes 
Worldwide, breast cancer is the most common cancer affecting women, representing one in 
four of all cancers in women. The incidence of breast cancer differs worldwide, with this 
disease being far more common in more developed countries compared with developing 
countries (although as less developed countries become more developed, a shift towards the 
lifestyles of developed countries brings an increase in cancers that have reproductive, dietary 
and hormonal risk factors, of which breast cancer is one) (UICC 2014). 
Breast cancer is the most commonly diagnosed cancer in Australian women (excluding basal 
and squamous cell carcinoma of the skin), comprising 27% of all female cancers, and with an 
incidence rate of around 115 new cases per 100,000 women (AIHW 2014). It is second only to 
lung cancer in cancer deaths in Australian women (AIHW 2014). 
For more information on breast cancer, see the Cancer Australia website, 
<www.canceraustralia.gov.au>. 
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1.2 Age is the greatest risk factor for breast cancer 
It is not known what causes breast cancer; however, several risk factors have been identified 
that may increase the chance of a woman developing breast cancer. Having a risk factor does 
not mean that a woman will get breast cancer—many women who have risk factors never 
develop breast cancer.  
The greatest risk factor for breast cancer is age, with most breast cancers occurring in women 
over the age of 50. Indeed, 77% of all breast cancers diagnosed in 2011 in Australia were in 
women aged 50 years and over. 
Certain reproductive or hormonal factors may also increase a woman’s risk of developing 
breast cancer, including not having carried or given birth to any children (or to fewer 
children), older age at birth of first child, younger age at menarche and older age at 
menopause. Oral contraception use can cause a small increase in the risk of breast cancer, as 
can hormone replacement therapy, which causes an increase in risk consistent with late 
menopause (De et al. 2010; McPherson et al. 2000). 
A family history of breast cancer can also increase a woman’s risk, although most women 
who develop breast cancer do not have a family history of the disease—8 out of 9 women 
who develop breast cancer do not have a mother, sister, or daughter with breast cancer 
(Breast Cancer Network Australia 2013). 
Family history can be split into three categories (Cancer Australia 2015a):  
• ‘At or slightly above average risk’ which covers more than 95% of the female population, 
and includes women with no family history as well as women with a weak family 
history (such as one first degree relative diagnosed with breast cancer at age 50 or older). 
Nine out of ten women in this group will not develop breast cancer. 
• ‘Moderately increased risk’ which covers less than 4% of the female population, and 
includes women with a strong family history (for instance, one first degree relative 
diagnosed with breast cancer under the age of 50). 
• ‘Potentially high risk’ which covers less than 1% of the female population, and includes 
women with a very strong family history (for instance, two first or second degree 
relatives on one side of the family diagnosed with breast or ovarian cancer plus one of a 
range of additional factors on the same side of the family, such as an additional breast 
cancer diagnosed before the age of 40, or breast cancer in a male relative). 
See Advice about familial aspects of breast cancer and epithelial ovarian cancer: a guide for health 
professionals (Cancer Australia 2015a) for more information about assessing individual risk 
and advice.  
Women with a BRCA1 or BRCA2 mutation have a higher risk of developing breast cancer 
compared with the general population in all age groups. Women who carry a fault in BRCA1 
or BRCA2 have a high lifetime risk of breast cancer, estimated to be in the range of 30–60%, 
and a lifetime ovarian cancer risk of about 20% (Cancer Australia 2015b). 
Women with dense breasts are also at an increased risk of developing breast cancer—around 
3–5 times higher for women with the most dense breasts compared with women with the 
least dense breasts. Other risk factors associated with breast cancer include a higher body 
mass index (BMI), exposure to X radiation and gamma radiation, and consumption of 
alcoholic beverages (Cancer Research UK 2014). 
The only factor protective against breast cancer is breastfeeding (WCRF/AICR 2007). 
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1.3 Screening can detect breast cancer early 
In Australia, population-based breast cancer screening is available through BreastScreen 
Australia, which targets women aged 50–74 for 2-yearly screening mammograms (women 
aged 40–49 and 75 years and over are also eligible to attend, but are not actively targeted). 
As with all population-based breast cancer screening programs, BreastScreen Australia aims 
to reduce morbidity and mortality from breast cancer by using screening mammograms to 
detect unsuspected breast cancers in women who have no symptoms and therefore would 
not otherwise know they had the disease. Detection of breast cancers at an early stage allows 
access to diagnostic and treatment services early, so that the woman can benefit the most 
from available treatments for breast cancer. Treatment options and survival are both 
increased when breast cancer is detected when it is small.  
Mammography is the only means of population-based screening shown to reduce breast 
cancer mortality, and is recommended as a population-based screening tool by Cancer 
Australia (Cancer Australia 2009). 
In screening mammography, two views are taken of each breast, and the images are 
reviewed by radiologists to look for suspicious characteristics that require further 
investigation. Screening mammography, like the screening tests used in other programs such 
as bowel and cervical screening, is not intended to be diagnostic; rather, it aims to identify 
people who are more likely to have breast cancer, and therefore require further investigation 
from diagnostic tests. 
Screening mammograms work well in older women because breasts become less dense as 
women get older, particularly after menopause, which is why mammograms become more 
effective as women get closer to age 50. Incidence of breast cancer is also much higher, with 
more than 75% of breast cancers occurring in women aged 50 and over.  
Mammographic screening is not recommended for women younger than 40. This is because 
breast tissue in premenopausal women tends to be dense, which can make it difficult to 
correctly identify the presence of breast cancer with mammography. The reduced accuracy 
of mammography in younger women produces a high risk of false positive and false 
negative results, which would result in a high number of unnecessary investigations and 
missed breast cancers (Irwig et al. 1997). 
Box 1.1: Women aged 40 and over are the focus of this report, but it is important 
for people of all ages to be breast-aware 
As women aged 40 and over are eligible for breast cancer screening through BreastScreen 
Australia, these women are the focus of this report. However, even though screening 
mammography is not recommended for women under the age of 40, young women can and 
do develop breast cancer. More rarely, men of any age can also develop breast cancer. 
Therefore, it is important for people of all ages to be aware of how their breasts normally 
look and feel and promptly report any new or unusual changes to their general 
practitioner. More information about breast cancer diagnosed in women aged under the age 
of 40 can be found in Breast cancer in young women: key facts about breast cancer in women in 
their 20s and 30s (AIHW 2015a).  
More information about breast cancer in men can be found at 
<http://breastcancerinmen.canceraustralia.gov.au>. 
 4 BreastScreen Australia monitoring report 2012–2013 
Screening mammography decreases mortality from breast cancer  
Lower morbidity from breast cancer is achieved by detecting cancers when they are small, as 
small breast cancers tend to be associated with increased treatment options (NBOCC 2009). 
Consistent with this, it has been shown that 58% of breast cancers detected by BreastScreen 
Australia are small, compared with just 28% of breast cancers detected outside BreastScreen 
Australia (NBOCC 2009). Further, treatment of breast cancers detected by BreastScreen 
Australia is more likely to be breast-conserving surgery (74% compared with 56% outside the 
program) (NBOCC 2009), which is associated with decreased morbidity. 
Mortality benefits from breast cancer screening are also due to the detection of breast cancers 
when they are small, as it has been shown that finding breast cancers when they are small 
leads to improved survival (AIHW & NBCC 2007). In 2009, in a comprehensive evaluation of 
BreastScreen Australia, it was estimated that breast cancer mortality had been reduced by 
21–28% as a result of breast cancer screening (BreastScreen Australia EAC 2009), and in 2010, 
it was estimated that 8.8 and 5.7 breast cancer deaths were prevented per 1,000 women 
screened using data from the Swedish Two-Country Trial and England’s breast cancer 
screening program, respectively (Duffy et al. 2010). 
In 2015, the International Agency for Research on Cancer (IARC) conducted a full review of 
available high-quality observational studies, to ensure that the evidence that showed a 
sufficient reduction in mortality from screening mammography compiled in 2002  
(IARC 2002) was still relevant today. The study determined that women aged 50–69 who 
attended breast cancer screening using screening mammography had about a 40% reduction 
in the risk of death from breast cancer, with a substantial reduction in the risk of death also 
observed in women aged 70–74 (IARC 2015). These mortality benefits align with the women 
targeted by BreastScreen Australia (that is, those aged 50–74).  
 
Box 1.2: ‘Overdiagnosis’ of breast cancer by BreastScreen Australia 
It is likely that some breast cancers detected through BreastScreen Australia may never have 
progressed to a stage where they would have been diagnosed during a woman’s lifetime. 
Detection of these cancers is sometimes referred to as ‘overdiagnosis’. 
It is estimated that for every 1000 women in Australia who are screened every two years from age 
50 to age 74, around 8 (between 2 and 21) breast cancers may be found and treated that would not 
have been found in a woman’s lifetime (Cancer Australia 2014). However, it is currently not 
possible to predict precisely which breast cancers would have progressed and which would 
not have progressed during a woman’s lifetime.  
Given these facts, the possibility of ‘overdiagnosis’ should not dissuade women from 
participating in breast cancer screening through BreastScreen Australia. 
For further information, please refer to the position statement endorsed by the Australian 
Health Ministers’ Advisory Council Standing Committee on Screening, Cancer Council 
Australia and the Royal Australian and New Zealand College of Radiologists, and 
supported by the Cancer Australia Advisory Council, which can be found at 
<http://canceraustralia.gov.au/publications-and-resources/position-
statements/overdiagnosis-mammographic-screening> (Cancer Australia 2014).  
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2 Recent change to the target age range 
of BreastScreen Australia  
2.1 Women aged 50–74 now targeted 
As part of the 2013–14 Federal Budget, the Australian Government committed $55.7 million 
over 4 years to expand BreastScreen Australia’s target age range from 50–69 to 50–74, 
resulting in a change to the age group actively targeted for 2-yearly screening mammograms.  
This means that, from 1 July 2013, women aged 70–74 began being actively targeted by 
BreastScreen Australia, along with women aged 50–69.  
Both the funding and the targeting activities associated with increasing the target age range 
by 5 years are being phased in over several years, with full implementation expected by 
2016–17. This means that participation of women aged 70–74 is likely to increase until  
2016–17, and thereafter be relatively stable (as illustrated in Figure 2.1 below). 
 
 
 
 
 
 
 
 
Figure 2.1: Transition of the target age range of BreastScreen Australia from women aged 50–69 to 
women aged 50–74 between the financial years 2013–14 and 2016–17 
2.2 Changes to reporting 
In order to report participation in a way that incorporates the new target age range yet is also 
comparable with previous years (and is thus a useful measure of performance), participation 
will be reported for both target age groups, women aged 50–69 and women aged 50–74, for 
several years, until the change has been fully implemented. 
The timing of commencement of this co-reporting has been considered carefully, as there is a 
discord between the implementation of the change in target age range (based on financial 
years to align with funding) and the reporting of participation data which are measured over 
two calendar years (from 1 January of the first year to 31 December of the second year). 
The plan for reporting the new target age group of BreastScreen Australia is detailed in Box 
2.1. This report, which covers the two calendar years 2012–2013, uses the target age group of  
50–69 as the target age range of BreastScreen Australia because the majority of the data that 
appear in this report were collected when only women aged 50–69 were actively targeted. 
 
Target age 
group 50–69 
Target age 
group 50–74 
Transition over 4 years 
2013–14 2016–17 
 6 BreastScreen Australia monitoring report 2012–2013 
Box 2.1: Reporting BreastScreen Australia’s new target age group  
The following is a brief summation of the plan for reporting from 2012–2013 onward: 
• Participation for 2012–2013 (1 January 2012 to 31 December 2013) will be reported for 
women aged 50–69 only, as there will be at most 6 months (from 1 July 2013 to 
31 December 2013) in which women aged 70–74 were also actively targeted. 
• Participation for 2013–2014 (1 January 2013 to 31 December 2014) will be reported for 
women aged 50–69 only, as there will be at most 18 months (from 1 July 2013 to 
31 December 2014) in which women aged 70–74 were also actively targeted. 
• Participation for 2014–2015 (1 January 2014 to 31 December 2015) onwards will be 
reported for both women aged 50–69 and women aged 50–74, as these reporting 
periods overlap completely with the implementation of the new target age range. 
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3 Monitoring BreastScreen Australia 
using program data 
3.1 Screening behaviour 
Screening behaviour in this report refers to participation in BreastScreen Australia 
(screening) and whether or not women return at 2-yearly intervals (rescreening).  
Note that these data to not include any screening mammography performed outside 
BreastScreen Australia (screening mammography is available through Medicare for women 
at higher risk of breast cancer, and mammograms are also undertaken in private clinics). 
Screening 
Participation is a major indicator of the performance of BreastScreen Australia, as high 
attendance for screening by women in the target age group maximises the reductions in 
mortality from breast cancer. Participation is measured as the percentage of women in the 
population aged 50–69 screened by BreastScreen Australia over 2 calendar years (Box 3.1).  
Box 3.1: Participation is measured over 2 calendar years 
Participation is measured over 2 years to align with the 2-year recommended screening 
interval, as most women will only screen once within a 2-year period. A consequence of 
measuring participation over 2 years on an annual basis is that there are ‘rolling’ 
participation rates, in which there is an overlap of 1 calendar year between any 2 
consecutive rates. Because of this, the participation rate for a 2-year reporting period is often 
compared with the previous non-overlapping rate.  
Preliminary participation data are released in July each year, with final comprehensive 
participation data published in this report. The latest preliminary participation data are for 
the two-year period 2013–2014, and the latest final participation data are for 2012–2013. 
In 2012–2013 and 2013–2014, the number of women aged 50–69 who participated in 
BreastScreen Australia was 1,439,748 and 1,456,830 respectively, which is 54.9% and 54.2% of 
the population, respectively.  
Participation rates for 2012–2013 and 2013–2014 have also been age-standardised to 54.4% 
and 53.7%, respectively, which are the rates used when comparing participation (and other 
measures of performance) over time or across population subgroups, such as states and 
territories, remoteness areas and socioeconomic status groups (see Box 3.2).  
Box 3.2: Crude versus age-standardised rates 
This report presents crude and age-standardised rates. Crude is the ‘true’ proportion or 
rate, and is appropriate when a single year or reporting period is reported (for example, 
crude participation in 2012–2013 was 54.9%). However, comparisons over time or across 
states/territories or population subgroups require that crude rates are age-standardised to 
remove underlying differences in age-structure over time or between groups. These allow 
analysis of trends and differentials, and are therefore preferentially reported in these 
situations (for example, the age-standardised participation rate in 2012–2013 was 54.4%). 
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Using the age-standardised rates allows us to see that participation in these latest years is 
similar to the participation in previous 2-year periods, as indicated by the dark blue line in 
Figure 3.1. This figure also shows that the number of women screened in each 2-year period 
(as indicated by the light blue columns) increases steadily from year to year.  
 
 
Note: Data for 2013–2014 are preliminary; data for all other reporting periods are final. 
Source: AIHW analysis of BreastScreen Australia data. Data for this figure are available in Table A1.1. 
Figure 3.1: Participation of women aged 50–69 in BreastScreen Australia, 1996–1997 to 2013–2014 
Rescreening 
As well as the proportion of women who screen in each 2-year period, the proportion of 
women who return for a rescreen is also monitored. It is important that women rescreen 
according to BreastScreen Australia’s recommended screening interval of 2 years, as it has 
been shown that screening intervals longer than 2 years reduce mortality benefits from 
screening and result in an increase in interval cancers (BreastScreen Australia 2004). This is 
because increased time between screening may allow a tumour to grow to the point where 
symptoms become evident, thus eliminating the advantage of screening. 
Although the recommended screening interval is 2 years (24 months), 27 months is used to 
allow a reasonable time frame for women to respond to invitations. The target age group 
used for rescreening is 50–67 rather 50–69, because women aged 68–69 at the age of their 
screen will be outside the target age group when they are due for their rescreen, and 
therefore will no longer be actively targeted by BreastScreen Australia. 
The latest rescreening data are for women screened in 2011; these show that for women 
screened for the first time in 2011, 59.6% of women aged 50–67 rescreened within 27 months. 
This increased to 67.8%of women who screened for the second time in 2011, and to 81.6% of 
women who screened for the third or subsequent time in 2011 (Figure 3.2). This indicates 
that the proportion of women aged 50–67 who return for a rescreen within 27 months 
increases with the number of screens previously attended.  
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It has been shown that women with false positive screening mammograms (that is, those 
recalled to assessment for further investigation and found not to have breast cancer) are less 
likely to participate in subsequent screening rounds (Sim et al. 2012). Since women are more 
likely to be recalled to assessment at their first screening visit (see Section 3.3), this may deter 
women from rescreening within the desired 27 months, which may contribute to the lower 
rescreening rates for women after their first screening visit. 
 
Note: Rates are the number of women rescreening within 27 months as a percentage of women screened and age-standardised to  
the population of women attending a BreastScreen service in 2008. 
Source: AIHW analysis of BreastScreen Australia data. Data for this figure are available in Table A2.1. 
Figure 3.2: Rescreening by screening round, women aged 50–67 screened during 2011  
Screening and rescreening behaviour across ages 
In both 2012–2013 and 2013–2014, the proportion of women screened was highest for those 
aged 50–69, in line with the BreastScreen Australia’s aim to maximise the proportion of 
women in the target age group screened every 2 years. Further, the proportion of women 
participating was around 49% or above for all 5-year age groups within the target age range, 
with participation highest for women aged 60–64, this being 59.5% in 2012–2013 (Figure 3.3) 
and 58.7% in 2013–2014. 
The proportion of women screened who were outside the target age group was lower, with 
around 15% of women aged 40–49 and around 14% of women aged 70 and over screened in  
2012–2013. In 2013–2014, the proportion of women screened aged 70 and over was higher at 
18%, which is likely due to women aged 70–74 being actively targeted by BreastScreen 
Australia from mid-2013. A similar trend was noted for women rescreening, with the highest 
rescreen rates for women aged 50–67, followed by women aged 40–49 in all three screening 
rounds. Women aged 70 and over had far lower rescreening rates regardless of the screening 
round (Figure 3.4). 
Women aged 50–67 comprise a greater proportion of women rescreening with increasing 
number of previous screens attended—59.6% of those rescreening after their first screen were 
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aged 50–67, whereas 67.8% of those rescreening after their second screen and 81.6% of all 
women rescreening after their third or subsequent screen were aged 50–67. 
 
Source: AIHW analysis of BreastScreen Australia data. Data for this figure are available in Table A1.2. 
Figure 3.3: Participation in BreastScreen Australia by age, 2012–2013  
 
 
Note: Rates are the number of women rescreening within 27 months as a percentage of women screened, age-standardised to the  
population of women attending a BreastScreen Australia service in 2008. 
Source: AIHW analysis of BreastScreen Australia data. Data for this figure are available in Table A2.2. 
Figure 3.4: Rescreening by age and screening round, women screened during 2011 
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Screening behaviour across groups 
Participation was highest in Outer regional areas at 59.2%, compared with 52.8% in Major 
cities and 47.3% in Very remote areas (Figure 3.5).  
There was little variation in participation across socioeconomic groups, with all groups 
having participation rates between 52.3% and 55.5% (Figure 3.5).  
 
 
Source: AIHW analysis of BreastScreen Australia data. Data for this figure are available in tables A1.4 and A1.5. 
Figure 3.5: Participation of women aged 50–69 in BreastScreen Australia, by remoteness area, and 
by socioeconomic status, 2012–2013 
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Aboriginal and Torres Strait Islander women participate in BreastScreen Australia at a lower 
rate than non-Indigenous women, with a difference of around 20 percentage points. This is 
also true to a lesser extent for women from culturally and linguistically diverse backgrounds, 
with participation for women who report that they speak a language other than English at 
home around 6 percentage points lower than for women who report that they only speak 
English and home.  
In 2012–2013, participation of Aboriginal and Torres Strait Islander women in BreastScreen 
Australia was 35.5% compared with the non-Indigenous rate of 54.5% (age-standardised), 
whereas participation of women who report that they speak a language other than English at 
home was 55.0% compared with the English-speaking rate of 48.8%. 
Participation trends for Aboriginal and Torres Strait Islander women and non-Indigenous 
women are shown in Figure 3.6. Historical Indigenous participation rates have been 
recalculated using new Indigenous population estimates so that meaningful comparisons 
between reporting periods can be made (see Box 3.3). 
Box 3.3: Indigenous populations 
New Indigenous population estimates were released by the Australian Bureau of Statistics 
(ABS) in 2014 based on the 2011 Census. These estimates included backcasts of the 
Indigenous population as well as population projections to 2026. The new backcast 
estimates of the Indigenous population were considerably larger than those previously 
published based on the 2006 Census. This is in part due to improvements in Census 
coverage and enumeration of Indigenous Australians in the 2011 Census, and an increased 
likelihood that individuals identified themselves and their children as Indigenous. 
Historical Indigenous participation rates have been recalculated using these new 
Indigenous population estimates so that meaningful comparisons between reporting 
periods can be made over time. Rates presented in this report should not be compared with 
previously published rates that used population estimates based on the 2006 Census. 
Trend data show that Indigenous women have always had lower participation rates than 
non-Indigenous women—at around 32–33% for all reporting periods between 2001–2002 and 
2011–2012, although increasing a little to 36% in 2012–2013 (Figure 3.6). Lower participation 
of Indigenous women may reflect a decreased opportunity to screen compared with non-
Indigenous women and/or different screening behaviour of Indigenous women (that is, 
being less likely to screen even with the same opportunity to do so).  
Results of a recent project, ‘Closing the Gap in Breast Cancer Screening’ (in Queensland), 
suggest that different screening behaviour of Indigenous women may play a significant role 
in their lower participation rates. This project aimed to address barriers to screening for 
Indigenous women through culturally appropriate messages, art shows and partnerships 
with local Indigenous groups, in order to build trust, educate and support Indigenous 
women to attend BreastScreen Australia. The project reported an increase in Indigenous 
participation from 49% to 56% in 2 years. 
Initiatives such as these are common to state and territory BreastScreen programs, many of 
which have adopted strategies and initiatives to encourage greater participation in breast 
cancer screening by Aboriginal and Torres Strait Islander women. These strategies and 
initiatives are designed to be culturally sensitive and appropriate to the knowledge, attitudes 
and beliefs of Aboriginal and Torres Strait Islander women. They include dedicated and 
appropriate communication resources, group bookings for Indigenous women who would 
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prefer to attend as a group, and the use of Indigenous artwork. BreastScreen workers liaise 
closely with Aboriginal Health Workers and Aboriginal and Torres Strait Islander 
community groups to increase acceptance of screening. 
In the last quarter of 2014–15, the Australian Government ran the National BreastScreen 
Australia Campaign to support the expansion of the program for women aged 50–74 years. 
The campaign included communication activities for Aboriginal and Torres Strait Islander 
consumers with materials developed in consultation with Aboriginal and Torres Strait 
Islander women. 
 
Note: The non-Indigenous participation rate excludes women with Indigenous status ‘not stated’ and is therefore lower than the total Australian 
participation rate.  
Source: AIHW analysis of BreastScreen Australia data. Data for this figure are available in Table A.1.7. 
Figure 3.6: Participation of women aged 50–69 in BreastScreen Australia, by Indigenous status, 
1996–1997 to 2012–2013 
Access to BreastScreen services, especially for women from Indigenous, culturally and 
linguistically diverse, rural/remote, and lower socioeconomic backgrounds is a national 
policy feature of BreastScreen Australia, which has developed National Accreditation 
Standard (NAS) Measures to ensure that this policy feature is met by services accredited 
through BreastScreen Australia (see Box 3.4 for more information on NAS Measures and 
accreditation). 
These NAS Measures, along with other NAS Measures related to access and participation in 
BreastScreen Australia underpin BreastScreen Australia’s aim to maximise the proportion of 
women in the target population who are screened every two years. 
Table 3.1 shows the NAS Measures related to participation and rescreening. 
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Table 3.1: NAS Measures for participation and rescreening calculated using BreastScreen Australia 
data supplied for the BreastScreen Australia monitoring report 2012–2013 
NAS Measure Calculated value 
NAS Measure 1.1.1 (b)  ≥70% of women aged 50–69 years participate in screening in the most 
recent 24-month period. 
54.4% 
 
NAS Measure 1.1.2 (b) ≥75% of women aged 50–67 years who attend for their first screening 
episode within the Program are rescreened within 27 months.  
59.6% 
NAS Measure 1.1.3 (b) ≥90% of women aged 50–67 years who attend for their second and 
subsequent screens within the Program are rescreened within 27 months 
of their previous screening episode. 
67.8% second 
81.6% subsequent 
NAS Measure 1.2.1 (b) The Service and/or SCU monitors and reports participation of women aged 
50–69 years from special groups and where rates are below that of the 
overall population, implements specific strategies to encourage their 
participation in screening. Consideration of equitable participation rates of 
at least the following groups is made: women from Indigenous, culturally 
and linguistically diverse, rural/remote and lower socio-economic 
backgrounds. 
Indigenous 
Non-English-speaking 
Remote/Very remote 
SES group (lowest) 
35.5% 
48.8% 
55.6%/47.3% 
52.3% 
NAS Measure 1.2.2  The Service and/or SCU monitors the proportion of all women in the 
Service who are screened and recalled for assessment, aged 40–49 years 
and 75 years and over. 
(a) women who are screened  
40–49 
75+ 
(b) women who are recalled for assessment 
40–49 
75+ 
15.4% 
14.2% 
 
10.7%/5.3% 
11.2%/4.2% 
Source: AIHW analysis of BreastScreen Australia data. 
Box 3.4: BreastScreen Australia and National Accreditation Standards 
Provision of a high-quality service to women is of great importance to BreastScreen 
Australia. For this reason, services accredited under BreastScreen Australia are expected to 
operate according to the National Accreditation Standards (NAS) of BreastScreen Australia, 
along with national policy features and protocols. The accreditation system, of which the 
NAS are an integral part, intends to drive continuous quality improvement in the delivery 
of breast screening services to ensure women receive safe, effective and high-quality care. 
The BreastScreen Australia NAS Measures have been developed to ensure that all women 
receive breast screening services that are of a consistently high quality, regardless of where 
they attend for screening or assessment. 
A number of NAS Measures are consistent with the performance indicators in this report. 
For this reason, where appropriate, the data in this report are benchmarked against these 
Measures. These benchmarks are useful in helping to interpret the data presented, although 
in considering how these national data compare with the NAS Measures, it should be noted 
that the NAS Measures were not designed to be used as standards for the BreastScreen 
Australia performance indicators. 
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3.2 Sensitivity of the screening test  
Mammography (X-ray of the breast) is the test used in breast cancer screening. Screening 
mammography, like the screening tests used in other programs such as bowel and cervical 
screening, is not intended to be diagnostic; rather, it aims to identify people who are more 
likely to have breast cancer, and therefore require further investigation from diagnostic tests. 
Sensitivity of a screening test is the ability of that test to accurately identify the disease in 
people who have that disease. This is referred to as a ‘true positive’ screening result. A ‘false 
negative’ screening result occurs when women have screening mammography that 
incorrectly indicates that they do not have breast cancer. 
The estimation of false negative results requires that we know if a woman had breast cancer 
present at the time of her screen. Because this cannot be truly known at the time of the test, 
we use interval cancers—breast cancers that arise between routine screening 
mammograms—as a way of assessing breast cancers that may have been present at the time 
of screen but missed by the screening process (although many interval cancers are not able to 
be detected because they were either not yet present or not visible—this is described in more 
detail in Box 3.5 and in the paragraphs that follow). 
Box 3.5: Interval cancers 
An interval cancer is defined as an invasive breast cancer that is diagnosed after a screening 
episode that detected no cancer and before the next scheduled screening episode (Kavanagh 
et al. 1999). This means that a woman attends BreastScreen for a screening mammogram, is 
advised that her mammogram is not suspicious for breast cancer, and given a 
recommendation to rescreen in 2 years (or in 1 year if she screens annually). Within those 
2 years (or 1 year in the case of the latter), she experiences signs or symptoms suggestive of 
breast cancer (such as a lump or clear or bloody nipple discharge), and either returns to 
BreastScreen or—more commonly—visits her general practitioner for further investigation, 
at which time it is discovered that she has invasive breast cancer. 
There are two categories of interval cancers; into which category an interval cancer falls can 
only be determined when previous screening mammograms are reviewed after the discovery 
of an interval cancer (for interval cancers diagnosed outside BreastScreen Australia, this 
discovery is made through linkage with the cancer registry in the relevant state or territory). 
All interval cancers in all state and territory BreastScreen programs undergo clinical review. 
The first category comprises ‘true’ interval cancers. These are invasive breast cancers 
diagnosed between routine screening mammograms that, upon review, could not be 
detected in the previous routine screening mammogram. This may be due to either the 
interval cancer being an aggressive breast cancer that emerged and grew very rapidly in the 
period between routine screening mammograms, or due to the breast cancer not being 
visible due to the characteristics of the cancer or the breast tissue (for example, dense breast 
tissue can make breast cancers very difficult to see). True interval cancers do not represent 
any failure in detection. 
The second category comprises breast cancers that, upon review, were visible in the previous 
routine screening mammogram. These are false negative screening results and are 
considered a failure of the screening process.  
However, even though only missed cancers and not ‘true’ interval cancers are false negative 
screening results, all interval cancers are included in this measure of sensitivity. 
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‘Program sensitivity’ is measured as the proportion of invasive breast cancers detected by 
BreastScreen Australia (screen-detected cancers) out of all invasive breast cancers (interval 
cancers plus screen-detected cancers) diagnosed in program-screened women in the 
screening interval. This program sensitivity is a measure of the sensitivity of screening 
mammography; that is, the proportion of breast cancers detected by BreastScreen Australia 
of all the breast cancers that may be present in screening women. 
How time since screen affects sensitivity  
The latest data for interval cancers and program sensitivity are for women screened in 2008, 
2009 and 2010 (referred to as index years 2008–2010). These are the latest data available 
because, by its very definition, at least 2 years need to have passed since a woman’s last 
routine screening mammogram to know whether she was diagnosed with an interval cancer 
in that time—often longer due to time required for cancer registries to be notified of the 
cancer, and for linkage between the BreastScreen registers and cancer registers. 
There are fewer interval cancers, and thus higher program sensitivity, in the first year 
following a woman’s negative screen than in the second year. For the index years 2008–2010, 
in the first year after a negative screening episode, there were 6 interval cancers per 10,000 
women-years after a woman’s first visit and subsequent visits. In comparison, in the second 
year after a negative screening episode, there were 10 and 12 interval cancers per 10,000 
women-years after a woman’s first visit and subsequent visits, respectively (Table 3.2). 
In these data, there were no appreciable differences in the interval cancer rate between first 
and subsequent screening rounds for either the first or second year after a negative screening 
episode (while in the second year after a negative screening round the interval cancer rate 
after a woman’s first screening round is slightly lower than after subsequent screening 
rounds at 10 compared with 12, the confidence intervals overlap which suggests that these 
two numbers do not differ in any significant way). This indicates that women are no more 
likely to have an interval cancer diagnosed after their first screen than after any other screen 
at BreastScreen Australia. This is different to invasive cancer detection through BreastScreen 
Australia, which is more likely at a woman’s first screen compared with subsequent screens 
(see Section 3.3). 
Program sensitivity differs by time since screen, being higher in the first year after a negative 
screening episode than when the entire 2 years are considered together (93.2% and 88.1% 
after a woman’s first visit and subsequent visits, respectively, compared with 85.6% and 
74.5% after a woman’s first visit and subsequent visits, respectively) (Table 3.2). 
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Table 3.2: Interval cancer rate and program sensitivity, by time since screen, women aged 50–69 
screened 2008–2010 
Time since screen First year after screen Second year after screen First and second years 
Interval cancers     
First screening round    
Number  134 210 344 
Crude rate  6.1 10.0 8.0 
AS rate  5.9 9.8 7.8 
95% CI  4.7–7.2 8.2–11.6 6.8–8.9 
Subsequent screening rounds    
Number  1,097 2,081 3,178 
Crude rate  6.1 12.2 9.1 
AS rate  6.1 12.1 9.0 
95% CI  5.8–6.5 11.6–12.6 8.7–9.4 
Program sensitivity     
First screening round    
Crude rate  92.4 . . 83.9 
AS rate  93.2 . . 85.6 
95% CI  88.3–98.2 . . 81.1–90.3 
Subsequent screening rounds    
Crude rate  88.8 . . 75.5 
AS rate  88.1 . . 74.5 
95% CI  86.2–90.1 . . 72.9–76.2 
. .  not applicable: program sensitivity is not calculated for the second year after a negative screening episode. 
Note: Crude rate is the number of interval cancers detected per 10,000 women-years; age-standardised (AS) rate is the number of interval 
cancers detected per 10,000 women-years, age-standardised to the population of women attending a BreastScreen Australia service in 2008; 
95% CI are 95% confidence intervals. 
Source: AIHW analysis of BreastScreen Australia data. 
Unlike the interval cancer measures, program sensitivity measures differ by screening round, 
being higher after a woman’s first visit compared with her subsequent visits. This may be 
because women at their first screening visit are more likely to be recalled to assessment for 
further investigation, and thus more likely to have a breast cancer that is present detected. 
How age affects sensitivity 
In 2008–2010, for the first year after a negative screening round, the interval cancer rate was 
lowest for women aged 50–59 and 60–69, and was highest for women aged 40–49. The trend 
was not as clear in the second year after a negative screening round, with the interval cancer 
rate lowest for women aged 40–49 and 50–59, increasing with increasing age (Table 3.3).  
Program sensitivity mirrored the trend seen in the first year after a negative screening round, 
being lowest for women aged 40–49, increasing with each 10-year age group to be highest for 
women aged 70 and over (Table 3.3). 
These results, when combined, point to lower sensitivity of screening mammography for 
women aged 40–49, meaning that BreastScreen Australia is less able to detect invasive breast 
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cancers in women aged 40–49 who attend for screening. This is likely due to features of 
young breasts, such as high density, which can make breast cancers difficult to visualise with 
mammography. 
Table 3.3: Interval cancer rate and program sensitivity, by age, women screened in 2008–2010 
Time since screen 
 Age group (years) 
 40–49 50–59 60–69 70+ 
Interval cancers     
First year Number  284 670 561 142 
 Crude rate  8.2 6.0 6.2 7.4 
Second year Number  388 1,173 1,118 287 
 Crude rate  11.9 11.0 13.1 15.8 
Program sensitivity     
First year Crude rate  79.0 87.3 91.1 92.9 
First and second years Crude rate  67.0 73.9 79.0 83.1 
Note: Crude rates are the number of interval cancers detected per 10,000 women-years. 
Source: AIHW analysis of BreastScreen Australia data. 
Specificity 
While sensitivity is the ability of a screening test to accurately identify the disease in people 
who have that disease, specificity refers to the ability of a screening test to accurately identify 
people who do not have the disease. This is referred to as a ‘true negative’ screening result. 
The vast majority of women who are given a negative screening result after their screening 
mammography through BreastScreen Australia do not have breast cancer, and thus receive a 
true negative screening result. 
Women who are not given a negative screening result are recalled to assessment for further 
investigation. A ‘true positive’ screening result is when they are found to have breast cancer 
at assessment. A ‘false positive’ screening result is when women are recalled to assessment 
for further investigation when they do not have breast cancer. Most women who are recalled 
to assessment through BreastScreen Australia do not have breast cancer. 
The proportion of women who are recalled to assessment will be examined in the following 
section (Section 3.3). BreastScreen Australia aims to achieve a balance in breast cancer 
screening that minimises the number of cancers that are missed (false negatives) while also 
minimising the number of women who are recalled when they do not have breast cancer 
(false positives). This underpins many of the objectives and NAS Measures of BreastScreen 
Australia. The NAS Measures related to interval cancers are shown in Table 3.4. 
Table 3.4: NAS Measures for interval cancers calculated using BreastScreen Australia data supplied 
for the BreastScreen Australia monitoring report 2012–2013 
NAS Measure Calculated value 
NAS Measure 2.3.1 (b) <7.5 per 10,000 women aged 50–69 years who attend for screening are 
diagnosed with an interval invasive breast cancer in the first calendar year 
following a negative screening episode. 
5.9/6.1 
NAS Measure 2.3.2 (b) ≤15 per 10,000 women aged 50–69 years who attend for screening are 
diagnosed with an interval invasive breast cancer in the second calendar 
year following a negative screening episode. 
9.8/12.1 
Source: AIHW analysis of BreastScreen Australia data. 
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3.3 Detection of invasive breast cancer and  
ductal carcinoma in situ (DCIS) 
At the completion of the screening episode, each woman screened through BreastScreen 
Australia receives what is called a ‘recommendation of screening’. For some women, this 
recommendation will be that she is recalled to an assessment centre to undergo further 
investigation because her mammogram was suspicious. 
The majority of women who participate in BreastScreen Australia experience only the 
screening test, while a subset—those who the screening test identify as being more likely to 
have breast cancer and therefore require further investigation from diagnostic tests—is 
recalled for more rigorous and sometimes invasive testing. Testing at assessment can include 
palpation, diagnostic mammography, ultrasound and, if required, a percutaneous biopsy  
(a fine needle or core biopsy of breast tissue upon which histology can be performed). 
In 2013, of the 86,038 women screened for the first time, 10,214 (11.9%) were recalled for 
further assessment, while of the 663,373 women attending subsequent screens, 25,681 (3.9%) 
were recalled. Of the women recalled to assessment, most were found not to have an 
invasive breast cancer or ductal carcinoma in situ (DCIS) detected—922 women attending 
their first visit, and 4,155 attending a subsequent screen had an invasive breast cancer or 
DCIS detected (Table 3.5). 
Table 3.5: Number of women aged 50–69 in who invasive breast cancer or DCIS was detected, 2013  
Number of women aged 50–69 First screening round Subsequent screening rounds 
Screened 86,038 663,373 
Recalled to assessment 10,214 25,681 
Invasive breast cancer or DCIS detected 922 4,155 
Source: AIHW analysis of BreastScreen Australia data. 
This means that, for women attending their first screen, 1.0% of women screened and 9.0% of 
women recalled to assessment will have an invasive breast cancer or DCIS detected, and for 
women attending subsequent screens, 0.6% of women screened and 16.2% of women 
recalled to assessment have an invasive breast cancer or DCIS detected. 
From this, it can be seen that screening mammography is less accurate for women attending 
for the first time, in so far as more women are recalled to assessment when there is no breast 
cancer or DCIS present (that is, have more false positives). This is likely due, in part, to not 
having any previous images with which to compare a woman’s first screening 
mammography images. Without any previous images for comparison, it is more difficult to 
distinguish between what is normal and what might be suspicious (BreastScreen WA 2008), 
with additional testing less likely when prior mammograms are available for comparison. 
Detection is usually expressed as the number of cancers diagnosed per 10,000 women 
screened. In 2013, for women aged 50–69, for every 10,000 women screened for the first time, 
83 had an invasive breast cancer detected, while for every 10,000 women attending 
subsequent screens, 49 had a cancer detected (Table 3.6). Detection of DCIS was rarer,  
at 24 per 10,000 women attending their first screen, and 13 per 10,000 women attending 
subsequent screens in 2013 (Table 3.6). 
A higher proportion of women attending their first screen have an invasive breast cancer or 
DCIS detected because a woman’s first visit detects prevalent cancers that may have been 
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present for some time rather than incident cancers that have grown between screens, which 
tend to be the breast cancers detected at subsequent screening visits (Kavanagh et al. 1999). 
Table 3.6: Invasive breast cancer and DCIS detection in women aged 50–69, 2013 
 Number Crude rate AS rate 95% CI 
Invasive breast cancer      
First screening round 715 83.1 107.9 97.9–118.5 
Subsequent screening rounds 3,279 49.4 47.6 45.9–49.2 
DCIS     
First screening round 207 24.1 29.2 24.2–34.7 
Subsequent screening rounds 876 13.2 12.8 12.0–13.7 
Note: Crude rate is the number of women with invasive breast cancer detected per 10,000 women screened; age-standardised (AS) rate is the 
number of women with invasive breast cancer detected per 10,000 women screened, age-standardised to the population of women attending a 
BreastScreen Australia service in 2008. AS rates are shown to aid in comparisons over time; 95%CI are 95% confidence intervals. 
Source: AIHW analysis of BreastScreen Australia data. 
Detection of small breast cancers 
BreastScreen Australia strives to maximise the detection of invasive breast cancers, 
particularly small cancers, to achieve the desired reductions in morbidity and mortality.  
In 2013, for every 10,000 women screened through BreastScreen Australia aged 50–69, 31 had 
a small (≤15 mm) invasive breast cancer detected. As a proportion of all invasive breast 
cancers detected, this was 46.3% for first screens, and 60.6% for subsequent screens. For all 
screening rounds combined, it was 58.0%. 
A woman is more likely to be diagnosed with a small cancer in subsequent screening visits 
than her first visit, since her first screening mammogram detects prevalent cancers that may 
have been present for some time, whereas subsequent screens detect incident cancers that 
have grown between screens (Kavanagh et al. 1999). Because they have had less time to 
grow, incident cancers are more likely to be small. 
Although the proportion of breast cancers detected that are small has fallen over time, from 
around 65% of all invasive breast cancers between 1996 and 2001 to 58% in 2013 (Figure 3.7), 
it is still of note that more than half of all invasive breast cancers detected through 
BreastScreen Australia are small at ≤15 mm. The high proportion of small breast cancers is a 
positive outcome, as small breast cancers tend to be associated with increased treatment 
options (NBOCC 2009) and improved survival (AIHW & NBCC 2007). Invasive breast 
cancers detected outside BreastScreen Australia are less likely to be small, with only 28% 
measuring ≤15 mm (NBOCC 2009).  
The proportion of cancers that are small is lower in younger age groups—46.7% for women 
aged 40–49 compared with 58.0% for women aged 50–69 and 59.2% for women aged 70 and 
over. The lower proportion of small invasive cancers in young age groups may be related to 
greater breast density in younger women, which makes small invasive breast cancers more 
difficult to detect using screening mammography (Irwig et al. 1997).  
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Source: AIHW analysis of BreastScreen Australia data. 
Figure 3.7: Number of invasive breast cancers, showing the proportion of small (≤15 mm) to 
other sizes (>15 mm), detected in women aged 50–69, all screening rounds, 1996 to 2013 
Detection over time 
Over time, while the recall to assessment rate for subsequent screening rounds has remained 
steady at 4%, the proportion of women attending BreastScreen Australia for the first time 
who were recalled to assessment has increased. After remaining steady at 10% from 2004 to 
2008, it increased to 11% in 2009–2012, before reaching a high of 11.6% in 2013 (Figure 3.8). 
Changes to recall to assessment rates should be considered alongside corresponding invasive 
cancer detection rates, as a higher recall to assessment rate may be considered acceptable 
(within reasonable limits) if it leads to higher breast cancer detection rates. 
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Source: AIHW analysis of BreastScreen Australia data. Data for this figure are available in Table A.3.1. 
Figure 3.8: Recall to assessment, women aged 50–69, first and subsequent screening rounds,  
1996 to 2013 
 
Invasive breast cancer detection trends are shown in Figure 3.9. For the past decade, the rate 
of invasive breast cancer detection for subsequent screening rounds has remained steady, 
ranging between 42 and 48 per 10,000 women screened. In contrast, after ranging between 72 
and 82 early in the past decade, invasive breast cancer detection increased to 92 in 2010, 
before falling back to 82 in 2011, and then increasing to 104 and 108 women diagnosed with 
invasive breast cancer per 10,000 women screened in 2012 and 2013, respectively (Figure 3.9). 
Detection of DCIS in women screening for the first time was also high in 2012 and 2013, 
reaching a high of 29 women diagnosed with DCIS per 10,000 women screened in 2013 
(Figure 3.10). 
Considering recall to assessment and invasive breast cancer detection rates together, it 
appears that the increase in the proportion of women who were recalled for further 
investigation in the last few years has led to an increase in the detection of breast cancer and 
DCIS for women screening for the first time. In this respect, the increase in the recall to 
assessment rate to above 10% for the first screening round may be considered acceptable. 
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Source: AIHW analysis of BreastScreen Australia data. Data for this figure are available in Table A.4.1 
Figure 3.9: Invasive breast cancer detection (all sizes), women aged 50–69, first and subsequent 
screening rounds, 1996 to 2013 
 
 
Source: AIHW analysis of BreastScreen Australia data. Data for this figure are available in Table A.5.1. 
Figure 3.10: DCIS detection, women aged 50–69, first and subsequent screening rounds,  
1996 to 2013 
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Detection across ages 
In 2013, the proportion of women attending their first screen that were recalled to assessment 
for further investigation was between 11% and 12% for all age groups aged 50 and over, with  
women aged 40–44 having a lower recall rate of 10% (Figure 3.11). 
This differed for women attending subsequent screens, for whom the proportion recalled to 
assessment was highest for women aged 40–44 and 45–49 at 5.2% and 5.3%, respectively. 
Women aged 55–69 were least likely to be recalled after a subsequent screen, having recall 
rates ranging between 3.6% and 3.8% of women screened in 2013 (Figure 3.11). 
 
Source: AIHW analysis of BreastScreen Australia data. Data for this figure are available in Table A.3.2. 
Figure 3.11: Recall to assessment by age, first and subsequent screening rounds, 2013 
Breast cancer detection increased with age in 2013, from 20 and 39 per 100,000 women 
screened for women aged 40–44 and 45–49, respectively, to 45 and 44 for women aged 50–54 
and 55–59, respectively, increasing to 57 and 70 for women aged 60–64 and 65–69, 
respectively. Breast cancer detection was highest for women aged 70 and over, with 96 
women diagnosed with invasive breast cancer for every 10,000 women screened  
(Figure 3.12). 
This trend of increasing invasive breast cancer detection with increasing age was true for 
both women attending their first screen and women attending subsequent screens  
(Figure 3.12). 
DCIS detection also increased with age. In 2013, DCIS detection was 12 per 10,000 women 
screened for women aged 40–49, 13 for women aged 50–59, 16 for women aged 60–69, and 19 
women diagnosed with DCIS per 10,000 women screened for ages 70 and over.  
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Source: AIHW analysis of BreastScreen Australia data. Data for this figure are available in Table A.4.4. 
Figure 3.12: Invasive breast cancer detection by age, first, subsequent and all screening rounds, 
2013 
BreastScreen Australia aims to maximise the number of invasive breast cancers and DCIS 
detected, while also minimising the number of women who are recalled when they do not 
have breast cancer (false positives). The NAS Measures related to invasive breast cancer 
detection, DCIS detection and recall to assessment are shown in Table 3.7. 
Table 3.7: NAS measures for the detection of invasive breast cancers, the detection of DCIS and 
recall to assessment calculated using BreastScreen Australia data supplied for the BreastScreen 
Australia monitoring report 2012–2013 
NAS Measure Calculated value 
NAS Measure 2.1.1 (b)  ≥50 per 10,000 women aged 50–69 years who attend for their first screening 
episode are diagnosed with invasive breast cancer. 
107.9 
 
NAS Measure 2.1.2 (b) ≥35 per 10,000 women aged 50–69 years who attend for their second or 
subsequent screening episode are diagnosed with invasive breast cancer. 
47.6 
NAS Measure 2.1.3 (c) ≥25 per 10,000 women aged 50–69 years who attend for screening are 
diagnosed with small (≤15mm) invasive breast cancer. 
30.4 
NAS Measure 2.2.1 (b) ≥12 per 10,000 women aged 50–69 years who attend for their first screening 
episode are diagnosed with DCIS. 
29.2 
NAS Measure 2.2.2 (b) ≥7 per 10,000 women aged 50–69 years who attend for their second or 
subsequent screening episode are diagnosed with DCIS. 
12.8 
NAS Measure 2.6.3 (b) <10% of women aged 50–69 years who attend for their first screening 
episode are recalled for assessment. 
11.6% 
NAS Measure 2.6.4 (b) <5% of women aged 50–69 years who attend for their second or subsequent 
screening episode are recalled for assessment. 
3.9% 
Source: AIHW analysis of BreastScreen Australia data. 
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4 Monitoring BreastScreen Australia 
using AIHW data 
4.1 Incidence of breast cancer 
Australia has high-quality and virtually complete cancer incidence data. Collected by state 
and territory cancer registries, clinical and demographic data for all cancer cases are 
provided to the Australian Institute of Health and Welfare (AIHW) and compiled into the 
Australian Cancer Database. The latest national data are for new cases diagnosed in 2011. 
In 2011, there were 14,465 new cases of breast cancer in Australian women. This is equivalent 
to 129 new cases for every 100,000 women in the population. Of the 14,465 new cases, 7,499 
were in women aged 50–69, the target population of BreastScreen Australia. These 7,499 new 
cases are equivalent to 297 new cases for every 100,000 women in the population. 
These rates have also been age-standardised for use in analyses of trends and differentials to 
116 new cases per 100,000 women for women of all ages, and 293 new cases per 100,000 
women for those aged 50–69. 
Box 4.1: Invasive breast cancer cases detected through BreastScreen Australia 
Of all invasive breast cancer cases diagnosed in 2011 in women aged 50–69, approximately 
45% were detected through BreastScreen Australia (32% for women aged 40 and over). 
Breast cancer types 
Invasive breast cancers by type are shown in Table 4.1 (2009 data are used instead of 2011, as 
2010 and 2011 data are estimates for New South Wales and the Australian Capital Territory).  
The most common breast cancer type for women aged 50–69 was invasive ductal carcinoma 
at 80.2% of all breast cancers; invasive lobular cancer was the second-most common at 11.0%. 
Table 4.1: Incidence of breast cancer in women aged 50–69, by type, 2009 
Type of breast cancer New cases Crude rate % of breast cancers 
Invasive ductal carcinoma 5,635 236.5 80.2 
Invasive lobular carcinoma 772 32.4 11.0 
Medullar carcinoma and atypical medullary carcinoma 28 1.2 0.4 
Tubular carcinoma and invasive cribriform carcinoma 146 6.1 2.1 
Mucinous carcinoma 95 4.0 1.4 
Invasive papillary carcinoma 72 3.0 1.0 
Inflammatory carcinoma 11 0.5 0.2 
Mesenchymal 7 0.3 0.1 
Other—specified 95 4.0 1.4 
Unspecified 165 6.9 2.4 
Note: Crude rate is the number of new cases per 100,000 women. Histology codes that comprise each breast cancer group appear in Appendix E  
Source: AIHW Australian Cancer Database 2011. 
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Other breast cancer types were rarer—ranging between less than 1 to 6 new cases per 100,000 
women aged 50–69 in the population. These accounted for 0.1% and 2.1% of all invasive 
breast cancers, respectively; unspecified breast cancers accounted for 2.4% (Table 4.1).  
Breast cancer over time 
The incidence rate for women aged 50–69, after increasing following the introduction of 
BreastScreen Australia in 1991, has been relatively steady at around 300 new cases per 
100,000 women (Figure 4.1).  
This is despite an increase in the number of new cases from 2,446 in 1982 to 7,499 in 2011 
(from 5,307 to 14,465 for women of all ages). 
 
 
Note: Rates age-standardised to the Australian population as at 30 June 2001. 
Source: AIHW Australian Cancer Database 2011. Data for this figure are available in Table A7.1. 
Figure 4.1: Incidence of breast cancer in women aged 50–69, 1982 to 2011 
Breast cancer across ages 
Incidence of breast cancer usually increases with increasing age, but the impact of 
BreastScreen Australia on the age at which breast cancers are diagnosed results in peak 
incidence occurring for women aged 60–64 and 65–69 at 346 and 370 new cases per 100,000 
women in 2011, respectively—both of which are higher than the incidence rates of the older 
age groups (Figure 4.2). 
In 2011, breast cancers in women aged 50–69 comprised half (51.8%) of all breast cancers 
diagnosed in that year. 
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Source: AIHW Australian Cancer Database. Data for this figure are available in Table A7.2. 
Figure 4.2: Incidence of breast cancer, by age, 2011 
Breast cancer across groups 
Incidence for population groups is presented for 2005–2009 (or 2006–2009 in the case of 
socioeconomic status) rather than for 2007–2011, as the actual data for 2010 and 2011 were 
not provided for New South Wales and the Australian Capital Territory to compile the 2011 
Australian Cancer Database (ACD) (see Appendix C). 
Although highest in Inner regional areas at 305 new cases per 100,000 women, incidence of 
breast cancer in 2005–2009 was relatively similar across all remoteness areas except for  
Very remote areas, which had a far lower incidence of 183 new cases per 100,000 women  
(Figure 4.3). 
Lower incidence in Very remote areas may be related to the proportionately high number of 
Aboriginal and Torres Strait Islander women living in these areas, since Indigenous women 
have lower incidence of breast cancer (see Figure 4.4). 
In 2006–2009, while incidence was relatively similar across socioeconomic status groups, 
there was a small trend of increasing incidence with increasing socioeconomic status  
(Figure 4.3).  
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Note: Rates age-standardised to the Australian population as at 30 June 2001. 
Source: AIHW Australian Cancer Database 2011. Data for this figure, including 95% confidence intervals, are available in tables A7.5 and A7.6. 
Figure 4.3: Incidence of breast cancer in women aged 50–69, by remoteness area, 2005–2009, and by 
socioeconomic status, 2006–2009 
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Box 4.2: Indigenous identification on the Australia Cancer Database 
The collection of reliable information by the state and territory cancer registries on the 
Indigenous status of individuals diagnosed with cancer is problematic. This is because 
primary cancer diagnosis information is sourced from pathology forms which currently do 
not record information on Indigenous status in most states and territories. The registries 
collect information on the Indigenous status of individuals from additional sources such as 
hospital records and death records, which affects the completeness (and quality) of data. 
This means that reliable national data on the incidence of cancer for Aboriginal and Torres 
Strait Islander Australians are not available, because in some jurisdictions the level of 
identification of Indigenous status is not considered sufficient to enable analysis. In this 
report, data for 4 states and territories—New South Wales, Queensland, Western Australia 
and the Northern Territory—are considered of sufficient quality, and were used to examine 
the incidence of breast cancer by Indigenous status. While the majority (around 85%) of 
Australian Aboriginal and Torres Strait Islander people reside in these 4 jurisdictions, both 
the level of completeness of Indigenous status recorded in these jurisdictions, and the 
degree to which data for these jurisdictions are representative of all Aboriginal and Torres 
Strait Islander people, is unknown. 
It was found that, over the 5-year period 2005–2009, breast cancer incidence in Aboriginal 
and Torres Strait Islander women aged 50–69 in New South Wales, Queensland, Western 
Australia and the Northern Territory was significantly lower than that of non-Indigenous 
women. This was 203 new cases per 100,000 Indigenous women compared with 271 new 
cases per 100,000 non-Indigenous women (Figure 4.4).  
 
Note: Rates age-standardised to the Australian population as at 30 June 2001; ‘Total’ rate includes women with a ‘not stated’ Indigenous status 
and is therefore greater than the ‘Non-Indigenous’ rate. 
Source: AIHW Australian Cancer Database 2011. Data for this figure, including 95% confidence intervals, are available in Table A7.7. 
Figure 4.4: Incidence of breast cancer in women aged 50–69 (New South Wales, Queensland, 
Western Australia and the Northern Territory), by Indigenous status, 2005–2009 
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4.2 Incidence of ductal carcinoma in situ (DCIS) 
DCIS is a non-invasive tumour arising from the lining of the ducts that carry milk from the 
milk-producing lobules to the nipple. Cell changes seen in DCIS are similar to those in 
invasive breast cancer. However, unlike invasive breast cancer, DCIS does not invade 
surrounding breast tissue, and is instead contained entirely within the milk duct. 
State and territory cancer registries have been collecting data on DCIS since 1996. Recently, 
these data have been included in data provided to the AIHW for the formation of the ACD; 
this means that for the first time, DCIS data have been sourced and analysed nationally 
through the ACD (see Appendix E for classification of DCIS). As actual data were not 
provided, data for New South Wales and the Australian Capital Territory had to be projected 
for 2010 and 2011 in the 2011 ACD, and as this does not include DCIS cases, there are no 
DCIS cases for New South Wales or the Australian Captial Territory for 2010 or 2011. 
Therefore, the latest national data for DCIS incidence are for 2009. 
In 2009, there were 1,803 new cases of DCIS in Australian women. This is equivalent to 17 
new cases for every 100,000 women in the population. Of the 1,803 new cases, 1,152 were in 
women aged 50–69, the target population of BreastScreen Australia. These 1,152 new cases 
are equivalent to 48 new cases for every 100,000 women in the population. 
These rates have also been age-standardised for use in analyses of trends and differentials to 
15 new cases per 100,000 women for women of all ages, and 48 new cases per 100,000 women 
for those aged 50–69.  
Box 4.3: DCIS cases detected through BreastScreen Australia 
Of all DCIS cases diagnosed in 2009 in women aged 50–69, approximately 76% were 
detected through BreastScreen Australia (65% for women aged 40 and over). 
DCIS over time 
Both the incidence rate and the number of new cases of DCIS in women aged 50–69 have 
increased over time; the former from 31 new cases per 100,000 women in 1996 to 48 in 2009, 
and the latter from 501 new cases in 1996 to 1,152 new cases in 2009. 
DCIS across ages 
Similar to invasive breast cancer, the incidence of DCIS increases with increasing age. Also 
similar to invasive breast cancer, there is a clear impact of BreastScreen Australia in 
determining the peak incidence of DCIS in women age 60–69. While DCIS incidence in 2009 
increased from 21 in women aged 40–49 to 44 in women aged 50–59 and finally to 55 for 
women aged 60–69, incidence of DCIS thereafter drops off to be 24 new cases per 100,000 
women for women aged 70 and over. 
In 2009, DCIS in women aged 50–69 comprised 64% of all cases diagnosed in that year. 
It is clear from these data, and the data shown in Box 4.3, that DCIS is deserving of its name 
as a ‘disease of screening’. Indeed, DCIS was rarely detected before breast screening was 
introduced, and its incidence has increased since the introduction of screening 
mammography, including that performed through BreastScreen Australia. 
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4.3 Mortality from breast cancer 
Similar to incidence data, Australia has high-quality and virtually complete mortality data. 
The mortality data used here were provided by the Registries of Births, Deaths and 
Marriages and the National Coronial Information System (managed by the Victorian 
Department of Justice) and include cause of death coded by the Australian Bureau of 
Statistics (ABS). These data are maintained at the AIHW in the National Mortality Database. 
The latest national data available are for deaths in 2012. 
In 2012, there were 2,795 deaths from breast cancer in Australian women. This is equivalent 
to 25 deaths for every 100,000 women in the population. Of the 2,795 deaths, 1,126 were in 
women aged 50–69, the target population of BreastScreen Australia. These 1,126 deaths are 
equivalent to 44 deaths for every 100,000 women in the population. 
These rates have also been age-standardised for use in analyses of trends and differentials to 
21 deaths per 100,000 women for women of all ages, and 42 deaths per 100,000 women for 
those aged 50–69. 
Breast cancer deaths over time 
Mortality from breast cancer has decreased over time, with this decrease evident after the 
introduction of BreastScreen Australia in 1991 when it was 68 deaths per 100,000 women to 
the rate in 2012 of 42 deaths per 100,000 women for women aged 50–69 (Figure 4.5). 
 
 
Notes  
1. Deaths from 1982 to 2011 were derived by year of death; deaths in 2012 were derived by year of registration of death. Deaths registered in 
2010 and earlier are based on the final version of cause-of-death data; deaths registered in 2011 and 2012 are based on revised and 
preliminary versions, respectively, and are subject to further revision by the ABS. 
2. Rates age-standardised to the Australian population as at 30 June 2001. 
Source: AIHW National Mortality Database. Data for this figure are available in Table A8.1. 
Figure 4.5: Mortality from breast cancer in women aged 50–69, 1982 to 2012 
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The fall in breast cancer mortality in women aged 50–69 has been attributed in part to the 
early detection of breast cancer through BreastScreen Australia, along with advances in the 
management and treatment of breast cancer (BreastScreen Australia EAC 2009). 
Breast cancer deaths across ages 
Mortality from breast cancer increases with increasing age. In 2012, this ranged from 
9 deaths per 100,000 women for women aged 40–44, to 177 deaths per 100,000 women for 
women aged 85 and over (Figure 4.6).  
In 2012, deaths due to breast cancer in women aged 50–69 comprised 40.3% of all breast 
cancer deaths in that year. 
 
Notes 
1. Rates are the number of deaths from breast cancer per 100,000 women. 
2. Deaths from 1991 to 2010 were derived by year of death; deaths in 2011 were derived by year of registration of death. Deaths registered 
in 2010 and earlier are based on the final version of cause of death data; deaths registered in 2010 and 2011 are based on revised and 
preliminary versions respectively, and are subject to further revision by the ABS. 
Source: AIHW National Mortality Database. Data for this figure are available in Table A8.2. 
Figure 4.6: Mortality from breast cancer, by age, 2012 
Breast cancer deaths across population groups 
Mortality in 2008–2012 for women aged 50–69 was relatively similar across Major cities, Inner 
regional and Outer regional areas, at around 44–46 deaths per 100,000 women. However, 
mortality was higher in Remote areas at 50 deaths per 100,000 women and lower in Very 
remote areas at 38 deaths per 100,000 women (Figure 4.7).  
The reason for higher mortality in Remote areas and lower mortality in Very remote areas in 
women age 50–69 years is not clear, but small numbers of deaths in Remote and Very remote 
areas (76 and 28, respectively) may affect the robustness of these rates. 
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Notes  
1. Deaths from 2008 to 2011 were derived by year of death; deaths in 2012 were derived by year of registration of death. Deaths registered in 
2010 and earlier are based on the final version of cause-of-death data; deaths registered in 2011 and 2012 are based on revised and 
preliminary versions, respectively, and are subject to further revision by the ABS. 
2.  Rates age-standardised to the Australian population as at 30 June 2001. 
Source: AIHW National Mortality Database. Data for this figure, including 95% confidence intervals, are available in Table A8.4. 
Figure 4.7: Mortality from breast cancer in women aged 50–69, by remoteness area, 2008–2012 
Information on Indigenous status in the AIHW National Mortality Database is considered to 
be adequate for reporting for 5 jurisdictions—New South Wales, Queensland, Western 
Australia, South Australia and the Northern Territory. The majority (around 90%) of 
Aboriginal and Torres Strait Islander people reside in these 5 jurisdictions.  
In 2008–2012, mortality from breast cancer in Aboriginal and Torres Strait Islander women 
aged 50–69 in New South Wales, Queensland, Western Australia, South Australia and the 
Northern Territory was significantly higher than that of non-Indigenous women. The 
mortality rate was 48 deaths per 100,000 Indigenous women compared with 44 deaths per 
100,000 non-Indigenous women (Figure 4.8). 
This higher mortality from breast cancer in Indigenous women is despite their having a 
lower incidence of breast cancer compared with non-Indigenous women. Higher mortality 
from breast cancer is associated with a larger size of breast cancer at diagnosis and spread of 
the cancer to lymph nodes (AIHW & NBCC 2007), and it has previously been shown that 
Aboriginal and Torres Strait Islander women have, on average, larger breast cancers, and a 
higher proportion of breast cancers that are node positive (Roder et al. 2012). 
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Notes  
1. Deaths from 2008 to 2011 are derived from year of death; deaths in 2012 are derived from year of registration. Deaths registered in 2010 
and earlier are based on the final version of cause-of-death data; deaths registered in 2011 and 2012 are based on revised and preliminary 
versions, respectively, and are subject to further revision by the ABS.  
2.  Rates age-standardised to the Australian population as at 30 June 2001. 
3.  ‘Total’ includes women for whom Indigenous status was ‘not stated’. 
Source: AIHW National Mortality Database. Data for this figure, including 95% confidence intervals, are available in Table A8.5. 
Figure 4.8: Mortality from breast cancer in women aged 50–69 (New South Wales, Queensland, 
Western Australia, South Australia and Northern Territory), by Indigenous status, 2008–2012 
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5 Monitoring other aspects of 
BreastScreen Australia 
5.1 Expenditure on BreastScreen Australia 
In Australia, there are three cancers for which screening is recommended—breast, cervical 
and bowel. Each cancer has a national screening program, with both Australian Government 
and state and territory government components.  
The Australian Government provides funding to the states and territories for public health 
services through National Health Reform Payments (known as National Specific Purpose 
Payments before 1 July 2012) and National Partnership Payments. State and territory 
governments have full discretion over the application of National Health Reform Payments 
for public health funding, including the amount expended on BreastScreen Australia and the 
National Cervical Screening Program. The funding for the National Bowel Cancer Screening 
Program is through a specific National Partnership Payment.  
In addition to the funding provided by the Australian Government, state and territory 
governments also contribute funding towards these programs. 
Table 5.1 shows expenditure for the three national cancer screening programs (expenditure 
by Australian and state and territory governments combined), as well as total expenditure on 
cancer screening for the 2012–13 financial year. 
In 2012–13, an estimated $204.9 million was spent on BreastScreen Australia. 
Table 5.1: Government funding for cancer screening programs, 2012–13 
Screening program Expenditure 2012–13 ($ million) 
BreastScreen Australia(a) 204.9 
National Cervical Screening Program(b) 89.3 
National Bowel Cancer Screening Program(c) 32.9 
Total 327.1 
(a) Excludes mammography for breast cancer screening that occurs outside BreastScreen Australia. 
(b) Excludes the proportion of the costs associated with general practitioner, specialist and nurse attendances that would have been for Pap 
smears. 
(c) Excludes Medicare Benefits Schedule (MBS) flow-on costs as well as bowel screening that occurs outside the National Bowel Cancer 
Screening Program. 
Note: These expenditure data only include recurrent expenditure; health infrastructure payments for cancer have been excluded as well as any 
health workforce expenditure. 
Sources: AIHW Health expenditure database; Medicare Australia Statistics. 
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Appendix A: Supporting data tables 
A1 Participation 
Table A1.1: Participation of women aged 50–69 in BreastScreen Australia, 1996–1997 to 2013–2014 
Reporting period Participants(a) Population(b) Crude rate(c) AS rate(d) 
1996–1997 845,143 1,637,010 51.6 51.7 
1997–1998 927,735 1,691,811 54.8 54.9 
1998–1999 976,182 1,744,201 56.0 56.0 
1999–2000 1,012,184 1,798,652 56.3 56.3 
2000–2001 1,064,246 1,856,598 57.3 57.3 
2001–2002 1,102,642 1,915,145 57.6 57.6 
2002–2003 1,118,823 1,974,192 56.7 56.6 
2003–2004 1,145,008 2,033,831 56.3 56.2 
2004–2005 1,188,955 2,094,183 56.8 56.7 
2005–2006 1,242,210 2,155,430 57.6 57.5 
2006–2007 1,262,334 2,217,714 56.9 56.7 
2007–2008 1,273,317 2,282,672 55.8 55.5 
2008–2009 1,319,771 2,349,050 56.2 55.9 
2009–2010 1,352,112 2,416,676 55.9 55.6 
2010–2011 1,373,731 2,487,062 55.2 54.8 
2011–2012 1,407,065 2,557,284 55.0 54.6 
2012–2013 1,439,748 2,624,718   54.9 54.4 
2013–2014 1,456,830 2,688,350 54.2 53.7 
(a) Participants are the number of women aged 50–69 screened through BreastScreen Australia in each 2-year reporting period. The screening 
periods cover 1 January of the initial year to 31 December of the latter year indicated. 
(b) Population is the average of the Australian Bureau of Statistics (ABS) estimated resident population for women aged 50–69 for the 
2 reporting years. 
(c) Crude rate is the number of women aged 50–69 screened in each 2-year reporting period as a percentage of the ABS estimated resident 
population. 
(d) Age-standardised (AS) rate is the number of women aged 50–69 screened in each 2-year reporting period as a percentage of the ABS 
estimated resident population age-standardised to the Australian population at 30 June 2001. 
Note: Data for 2013–2014 are preliminary; data for all other reporting periods are final. 
Source: AIHW analysis of BreastScreen Australia data. 
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Table A1.2: BreastScreen Australia participation by age, 2012–2013 and 2013–2014 
 40–44 45–49 50–54 55–59 60–64 65–69 70+ 
2012–2013        
Number 95,962 151,224 382,542 378,326 369,518 309,362 174,968 
Crude rate 11.5 19.6 49.3 54.2 59.5 58.4 14.2 
2013–2014        
Number 100,882 149,480 380,921 378,684 372,144 325,081 224,352 
Crude rate 12.0 19.3 48.5 53.0 58.7 58.6 17.7 
Notes 
1. For 2012–2013 data, Crude rate is the number of women screened in 2012–2013 as a percentage of the ABS estimated resident 
population. 
2. Data for 2013–2014 are preliminary. 
Source: AIHW analysis of BreastScreen Australia data. 
 
Table A1.3: BreastScreen Australia participation by state and territory, women aged 50–69,  
2012–2013 and 2013–2014 
 NSW Vic Qld WA SA Tas ACT NT Australia 
2012–2013          
Number 445,023 356,963 302,281 154,170 110,419 39,768 22,441 8,683 1,439,748 
Crude rate 52.1 55.3 58.0 57.3 53.6 58.7 55.5 41.4 54.9 
AS rate 51.6 54.9 57.6 57.1 53.1 57.9 54.9 41.6 54.4 
2013–2014          
Number 448,290 362,644 307,941 150,466 116,900 39,410 22,621 8,558 1,456,830 
Crude rate 51.3 54.8 57.6 54.4 55.7 57.2 54.8 39.7 54.2 
AS rate 50.7 54.5 57.2 54.1 54.9 56.4 54.2 39.7 53.7 
Notes 
1. For 2012–2013 data, Crude rate is the number of women screened in 2012–2013 as a percentage of the ABS estimated resident 
population; age-standardised (AS) rate is the number of women screened in 2012–2013 as a percentage of the ABS estimated resident 
population age-standardised to the Australian population at 30 June 2001. 
2. Direct comparisons between the states and territories of Australia are not advised due to the substantial differences that exist between the 
jurisdictions including for population, geographical size and structure, policies and other factors. 
3. Data for 2013–2014 are preliminary. 
Source: AIHW analysis of BreastScreen Australia data. 
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Table A1.4: BreastScreen Australia participation by remoteness area, women aged 50–69, 2012–2013 
 Major cities Inner regional Outer regional Remote Very remote Australia 
Number 944,408 316,699 151,739 18,111 7,950 1,439,748 
Crude rate 53.2 58.1 59.7 55.7 47.2 54.9 
AS rate 52.8 57.4 59.2 55.6 47.3 54.4 
Notes 
1. Crude rate is the number of women screened in 2012–2013 as a percentage of the ABS estimated resident population; age-standardised 
(AS) rate is the number of women screened in 2012–2013 as a percentage of the ABS estimated resident population age-standardised to 
the Australian population at 30 June 2001. 
2. Remoteness areas were assigned using the woman’s residential postcode according to the Australian Statistical Geography Standard 
(ASGS) for 2011. Not all postcodes can be assigned to a remoteness area therefore, categories do not add exactly to the total for Australia. 
Source: AIHW analysis of BreastScreen Australia data. 
Table A1.5: BreastScreen Australia participation by socioeconomic status, women aged 50–69,  
2012–2013 
 1 (lowest) 2 3 4 5 (highest) Australia 
Number 281,752 297,827 286,160 283,285 287,291 1,439,748 
Crude rate 52.9 56.1 55.0 55.3 54.3 54.9 
AS rate 52.3 55.5 54.6 55.0 54.0 54.4 
Notes 
1. Crude rate is the number of women screened in 2012–2013 as a percentage of the ABS estimated resident population; age-standardised 
(AS) rate is the number of women screened in 2012–2013 as a percentage of the ABS estimated resident population age-standardised to 
the Australian population at 30 June 2001.  
2. Socioeconomic status was assigned using the woman’s residential postcode according to the Socio-Economic Indexes for Areas (SEIFA) 
Index of Relative Socio-economic Disadvantage for 2011; 1 (lowest socioeconomic group) corresponds to the most disadvantaged 
socioeconomic status and 5 (highest socioeconomic group) to the least disadvantaged socioeconomic status. Not all postcodes could be 
assigned to a socioeconomic category; therefore, categories do not add exactly to the total for Australia. 
Source: AIHW analysis of BreastScreen Australia data. 
Table A1.6: BreastScreen Australia participation by Indigenous status, women aged 50–69,  
2012–2013 
(a) Includes women in the ‘not stated’ category for Indigenous status. Therefore, columns may not sum to the Australia column. 
Notes 
1. Indigenous status is self-reported; therefore, accuracy of Indigenous participation rates will be affected if women choose not to identify as 
Indigenous at the time of screening.  
2. Crude rate is the number of women screened in 2012–2013 as a percentage of the ABS estimated resident population; age-standardised 
(AS) rate is the number of women screened in 2012–2013 as a percentage of the ABS estimated resident population age-standardised to 
the Australian population at 30 June 2001. 
Source: AIHW analysis of BreastScreen Australia data. 
  
 Indigenous Non-Indigenous Australia(a) 
Number 14,786 1,418,450 1,439,748 
Crude rate 35.1 54.9 54.9 
AS rate 35.5 54.5 54.4 
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Table A1.7: Number and age-standardised rate of women aged 50–69 participating in BreastScreen 
Australia, by Indigenous status, 1996–1997 to 2012–2013 
Reporting  
period 
Indigenous 
participants 
Indigenous 
crude rate 
Indigenous  
AS rate 
Non-Indigenous 
participants 
Non-Indigenous 
crude rate 
Non-Indigenous  
AS rate 
1996–1997 4,660 25.0 25.0 643,182   39.7 39.8 
1997–1998 5,398 27.8 27.8 713,175 42.6 42.7 
1998–1999 5,965 29.3 29.4 748,367 43.4 43.4 
1999–2000 6,479 30.4 30.5 773,574 43.5 43.5 
2000–2001 7,011 31.4 31.5 813,461 44.3 44.4 
2001–2002 7,504 31.9 32.1 849,334 44.9 44.9 
2002–2003 7,985 32.3 32.6 985,439 50.5 50.5 
2003–2004 8,132 31.2 31.5 1,131,173 56.3 56.3 
2004–2005 8,595 31.2 31.6 1,175,197 56.9 56.8 
2005–2006 9,284 32.0 32.4 1,226,306 57.7 57.5 
2006–2007 9,720 31.7 32.1 1,246,513   57.0 56.8 
2007–2008 10,294 31.9 32.3 1,256,472 55.8 55.6 
2008–2009 10,902 31.9 32.3 1,302,050   56.2 55.9 
2009–2010 11,374 31.5 32.0 1,332,597   56.0 55.6 
2010–2011 11,971 31.5 31.9 1,341,869   54.8 54.4 
2011–2012 13,164 32.9 33.3 1,384,064 55.0 54.5 
2012–2013 14,786 35.1 35.5 1,418,450 54.9 54.5 
Notes 
1. Indigenous status is self-reported; therefore, accuracy of Indigenous participation rates will be affected if women choose not to identify as 
Indigenous at the time of screening.  
2. Crude rate is the number of women screened  as a percentage of the ABS estimated resident population; age-standardised (AS) rate is the 
number of women screened as a percentage of the ABS estimated resident population age-standardised to the Australian population at 30 
June 2001. 
Source: AIHW analysis of BreastScreen Australia data. 
Table A1.8: BreastScreen Australia participation by main language spoken at home, women aged  
50–69, 2012–2013 
(a) Includes women in the ‘not stated’ category for main language other than English spoken at home. Therefore, columns may not sum to the 
Australia column. 
Notes 
1. Some jurisdictions do not use the ‘not stated’ category, and there may also be differences in how these data are collected. This means that 
the analysis based on main language spoken at home should be interpreted with caution. 
2. Crude rate is the number of women screened in 2012–2013 as a percentage of the ABS estimated resident population; age-standardised 
(AS) rate is the number of women screened in 2012–2013 as a percentage of the ABS estimated resident population age-standardised to 
the Australian population at 30 June 2001. 
Source: AIHW analysis of BreastScreen Australia data. 
 English-speaking Non-English-speaking Australia(a) 
Number  1,209,575 218,476 1,439,748 
Crude rate 55.5 49.1 54.9 
AS rate 55.0 48.8 54.4 
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A2 Rescreening 
Table A2.1: Rescreening by screening round, women aged 50–67, 2001 to 2011 
 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 
First screening round 
AS rate 62.8 61.5 60.4 62.7 59.3 49.9 55.9 59.9 59.4 58.3 59.6 
Second screening round 
AS rate 71.9 70.2 69.3 70.5 66.8 58.5 62.6 71.2 69.8 67.8 67.8 
Third and subsequent screening rounds 
AS rate 81.9 80.8 80.2 81.0 78.4 73.5 76.1 81.6 82.3 82.8 81.6 
Note: Age-standardised (AS) rate is the number of women rescreened within 27 months as a percentage of women screened age-standardised to 
the population of women attending a BreastScreen Australia service in 2008. 
Source: AIHW analysis of BreastScreen Australia data. 
Table A2.2: Rescreening by age and screening round, women screened during 2011 
 Age group (years) 
 40–49 50–67 70+ 
First screening round  
Crude rate 45.8 60.1 28.7 
Second screening round 
Crude rate 65.7 68.9 39.6 
Third and subsequent screening rounds 
Crude rate 80.0 81.7 54.1 
Note: Crude rate is the number of women rescreened within 27 months as a percentage of women screened. 
Source: AIHW analysis of BreastScreen Australia data. 
Table A2.3: Rescreening by state and territory and screening round, women aged 50–67 screened 
during 2011 
 NSW Vic Qld WA SA Tas ACT NT Australia 
First screening round 
Crude rate 65.1 58.2 62.9 61.1 44.4 69.9 50.2 41.4 60.1 
AS rate 64.9 53.9 63.2 56.6 43.8 70.6 45.1 38.9 59.6 
Second screening round 
Crude rate 73.5 67.4 71.7 71.8 50.2 76.7 61.4 51.1 68.9 
AS rate 72.2 63.8 71.8 68.8 49.3 77.2 56.6 49.0 67.8 
Third and subsequent screening rounds  
Crude rate 85.5 79.7 85.9 82.9 64.1 86.0 70.9 68.1 81.7 
AS rate 85.2 79.5 85.7 82.9 64.0 85.8 70.5 68.3 81.6 
Note: Crude rate is the number of women rescreened within 27 months as a percentage of women screened; age-standardised (AS) rate is the 
number of women rescreened within 27 months as a percentage of women screened age-standardised to the population of women attending a 
BreastScreen Australia service in 2008. 
Source: AIHW analysis of BreastScreen Australia data. 
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A3 Recall to assessment  
Table A3.1: Recall to assessment, women aged 50–69, first and subsequent screening rounds,  
2003 to 2013 
 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 
First screening round 
Number 6,320 7,061 7,503 7,743 7,948 9,213 9,454 9,110 8,420 8,395 10,214 
Crude rate 9.5 10.0 10.2 10.2 10.3 10.3 11.2 11.4 11.1 10.8 11.9 
AS rate 9.4 9.8 9.8 9.9 9.9 9.9 10.7 11.1 10.7 10.8 11.6 
Subsequent screening rounds 
Number 20.845 21,292 21,851 23,078 22,472 23,604 25,164 25,880 24,022 22,406 25,681 
Crude rate 4.0 4.0 3.9 4.0 4.0 4.1 4.1 4.1 3.7 3.4 3.9 
AS rate 4.0 4.0 3.9 4.0 4.0 4.1 4.2 4.2 3.8 3.4 3.9 
Note: Crude rate is the number of women recalled for assessment as a percentage of women screened; age-standardised (AS) rate is the number 
of women recalled for assessment as a percentage of women screened age-standardised to the population of women attending a BreastScreen 
Australia service in 2008. 
Source: AIHW analysis of BreastScreen Australia data. 
Table A3.2: Recall to assessment by age, first and subsequent screening rounds, 2013 
 Age group (years) 
 40–44 45–49 50–54 55–59 60–64 65–69 70+ 
First screening round 
Number 3,897 3,669 6,901 1,762 985 566 256 
Crude rate 10.0 11.5 12.1 11.6 11.4 11.3 11.2 
Subsequent screening rounds 
Number 769 2,569 6,328 6,542 6,703 6,108 4,167 
Crude rate 5.2 5.3 4.5 3.6 3.7 3.8 4.2 
Note: Crude rate is the number of women recalled for assessment as a percentage of women screened. 
Source: AIHW analysis of BreastScreen Australia data. 
Table A3.3: Recall to assessment by state and territory, women aged 50–69, first and subsequent 
screening rounds, 2013  
 NSW Vic Qld WA SA Tas ACT NT Australia 
First screening round 
Number 3,641 3,021 1,664 750 720 157 133 128 10,214 
Crude rate 12.7 11.9 13.1 8.2 14.1 9.4 6.4 10.4 11.9 
AS rate 12.4 11.9 13.3 7.7 14.6 8.7 6.5 9.2 11.6 
Subsequent screening rounds 
Number 8,467 6,125 6,105 1,629 2,334 572 327 122 25,681 
Crude rate 4.1 3.8 4.1 2.3 5.0 3.0 3.2 3.4 3.9 
AS rate 4.2 3.9 4.2 2.3 5.0 3.0 3.2 3.4 3.9 
Note: Crude rate is the number of women recalled for assessment as a percentage of women screened; age-standardised (AS) rate is the number 
of women recalled for assessment as a percentage of women screened age-standardised to the population of women attending a BreastScreen 
Australia service in 2008. 
Source: AIHW analysis of BreastScreen Australia data. 
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A4 Invasive breast cancer detection 
Table A4.1: All-size invasive breast cancer detection in women aged 50–69, first and subsequent 
screening rounds, 2003 to 2013 
 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 
First screening round 
Number 421 465 475 442 489 585 549 581 537 631 715 
Crude rate  63.5 66.1 64.5 58.4 63.6 67.2 65.2 72.7 70.7 80.8 83.1 
AS rate 74.2 82.2 76.6 71.8 77.6 75.5 79.5 91.6 82.1 103.6 107.9 
95% CI 66.0–
82.9 
73.3–
91.8 
68.4–
85.4 
63.8–
80.4 
69.8–
86.0 
68.5–
82.9 
71.7–
87.7 
82.6–
101.2 
73.5–
91.3 
93.2–
114.6 
97.9–
118.5 
Subsequent screening rounds 
Number 2,302 2,313 2,371 2,589 2,437 2,834 2,859 2,879 2,862 3,011 3,279 
Crude rate 44.4 43.5 42.5 44.4 43.0 48.7 46.8 45.9 44.4 45.4 49.4 
AS rate  44.2 43.3 42.1 44.0 42.3 47.8 45.4 44.4 42.9 43.9 47.6 
95% CI 42.4–
46.1 
41.5–
45.1 
40.5–
43.9 
42.3–
45.7 
40.7–
44.0 
46.0–
49.6 
43.8–
47.1 
42.8–
46.1 
41.3–
44.5 
42.4–
45.5 
45.9–
49.2 
Note: Crude rate is the number of women with invasive breast cancer detected per 10,000 women screened; age-standardised (AS) rate is the 
number of women with invasive breast cancer detected per 10,000 women screened, age-standardised to the population of women attending a 
BreastScreen Australia service in 2008; 95% CI are 95% confidence intervals. 
Source: AIHW analysis of BreastScreen Australia data. 
Table A4.2: Small (≤15 mm) invasive breast cancer detection in women aged 50–69, all screening 
rounds, 2003 to 2013 
 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 
Number 1,695 1,763 1,797 1,898 1,798 2,103 2,132 2,082 2,077 2,122 2,317 
Crude rate 29.0 29.3 28.4 28.8 27.9 31.4 30.7 29.4 28.8 28.6 30.9 
AS rate 29.4 29.6 28.7 29.2 28.0 31.4 30.5 29.2 28.4 28.2 30.4 
95% CI 28.0–
30.9 
28.3–
31.0 
27.4–
30.1 
27.9–
30.5 
26.7–
29.3 
30.1–
32.8 
29.2–
31.8 
27.9–
30.4 
27.2–
29.7 
27.1–
29.5 
29.1–
31.6 
Note: Crude rate is the number of women with invasive breast cancer detected per 10,000 women screened; age-standardised (AS) rate is the 
number of women with invasive breast cancer detected per 10,000 women screened, age-standardised to the population of women attending a 
BreastScreen Australia service in 2008; 95% CI are 95% confidence intervals. 
Source: AIHW analysis of BreastScreen Australia data. 
Table A4.3: Proportion of small (≤15 mm) invasive breast cancers detected in women aged 50–69,  
all screening rounds, 2003 to 2013 
 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 
Proportion (%) 62.2 63.5 63.1 62.6 61.4 61.5 62.6 60.2 61.1 58.3 58.0 
Note: Figures are the number of women with small invasive breast cancer detected as a proportion of the number of women with invasive breast 
cancer detected. 
Source: AIHW analysis of BreastScreen Australia data. 
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Table A4.4: All-size and small (≤15 mm) invasive breast cancer detection by age, all screening 
rounds, 2013 
 Age group (years) 
 40–44 45–49 50–54 55–59 60–64 65–69 70+ 
All-size        
Number 110 316 903 860 1,083 1,148 968 
Crude rate 20.3 39.3 45.3 44.1 56.7 70.1 96.2 
Small        
Number 51 148 488 484 646 699 573 
Crude rate 9.4 18.4 24.5 24.8 33.8 42.7 57.0 
Note: Crude rate is the number of women with small invasive breast cancer detected per 10,000 women screened. 
Source: AIHW analysis of BreastScreen Australia data. 
Table A4.5: All-size and small (≤15 mm) invasive breast cancer detection by state and territory, 
women aged 50–69, 2013 
 NSW Vic Qld WA SA Tas ACT NT Australia 
All-size, first screening round 
Number 231 183 112 78 37 14 52 8 715 
Crude rate 80.3 72.2 88.3 85.0 72.6 83.6 250.1 64.8 83.1 
AS rate 108.6 91.8 102.1 100.9 100.6 91.9 251.1 80.5 107.9 
95% CI 
91.0– 
128.0 
73.5– 
112.3 
81.0– 
126.5 
72.1– 
135.0 
59.2– 
153.6 
43.6– 
164.2 
186.2– 
330.9 
18.0–
187.3 
97.9– 
118.5 
All-size, subsequent screening rounds 
Number 966 834 730 343 266 98 22 20 3,279 
Crude rate 47.0 52.0 49.6 48.4 56.8 51.7 21.6 56.3 49.4 
AS rate 44.9 49.9 48.5 46.7 53.8 50.6 21.0 53.8 47.6 
95% CI 
42.0– 
47.9 
46.5– 
53.4 
45.0– 
52.1 
41.8– 
52.0 
47.4– 
60.8 
40.9– 
61.9 
13.1– 
31.8 
32.8– 
83.2 
45.9– 
49.2 
Small, all screening rounds 
Number 701 559 491 242 194 84 30 16 2,317 
Crude rate 29.9 30.1 30.7 30.2 37.4 40.7 24.4 33.4 30.9 
AS rate 29.2 29.6 30.4 30.1 36.1 39.9 24.4 36.7 30.4 
95% CI 27.1–31.5 27.2–32.1 27.7–33.2 26.4–34.1 31.2–41.6 31.8–49.5 16.4–35.0 20.8–60.0 29.1–31.6 
Notes 
1. Crude rate is the number of women with invasive breast cancer detected per 10,000 women screened; age-standardised (AS) rate is the 
number of women with invasive breast cancer detected per 10,000 women screened, age-standardised to the population of women 
attending a BreastScreen Australia service in 2008; 95% CI are 95% confidence intervals. 
2. State and territory differences, along with the size of the 95% confidence intervals (particularly in the smaller states and territories), need to 
be taken into consideration when interpreting cancer detection results. 
3. A small number of women may be screened in one jurisdiction but have their cancer detected in another. 
Source: AIHW analysis of BreastScreen Australia data. 
  
  BreastScreen Australia monitoring report 2012–2013 45 
A5 Ductal carcinoma in situ (DCIS) detection 
Table A5.1: DCIS detection by year, women aged 50–69, first and subsequent screening rounds,  
2003 to 2013 
 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 
First screening round 
Number 105 123 104 130 144 142 152 142 141 153 207 
Crude rate 15.8 17.5 14.1 17.2 18.7 15.9 18.0 17.8 18.6 19.6 24.1 
AS rate 16.7 20.4 14.5 18.8 21.3 15.6 19.6 17.9 20.9 22.8 29.2 
95% CI 13.0– 
21.0 
16.1– 
25.4 
11.2– 
18.4 
14.9– 
23.3 
17.3– 
25.7 
12.7– 
18.8 
16.0– 
23.6 
14.1– 
22.1 
16.7– 
25.7 
18.1– 
28.0 
24.2– 
34.7 
Subsequent screening rounds 
Number 537 565 618 571 633 678 723 734 740 750 876 
Crude rate 10.4 10.6 11.1 9.8 11.2 11.7 11.8 11.7 11.5 11.3 13.2 
AS rate 10.3 10.7 11.0 9.7 11.1 11.5 11.7 11.5 11.2 11.0 12.8 
95% CI 9.4– 
11.2 
9.8– 
11.6 
10.2– 
11.9 
8.9– 
10.6 
10.3– 
12.0 
10.7– 
12.4 
10.9– 
12.6 
10.7– 
12.4 
10.4– 
12.1 
10.3– 
11.9 
12.0– 
13.7 
Note: Crude rate is the number of women with DCIS detected per 10,000 women screened; age-standardised (AS) rate is the number of women 
with DCIS detected per 10,000 women screened, age-standardised to the population of women attending a BreastScreen Australia service in 
2008; 95% CI are 95% confidence intervals. 
Source: AIHW analysis of BreastScreen Australia data. 
Table A5.2: DCIS detection by age, all screening rounds, 2013 
 Age group (years) 
 40–49 50–59 60–69 70+ 
Number 155 527 556 192 
Crude rate 11.5 13.4 15.7 19.1 
Note: Crude rate is the number of women with DCIS detected per 10,000 women screened. 
Source: AIHW analysis of BreastScreen Australia data. 
Table A5.3: DCIS detection by state and territory, women aged 50–69, all screening rounds, 2013  
 NSW Vic Qld WA SA Tas ACT NT Australia 
Number 337 272 208 129 79 31 18 9 1,083 
Crude rate 14.4 14.6 13.0 16.1 15.2 15.0 14.7 18.8 14.5 
AS rate 14.3 14.6 12.9 16.1 15.0 14.4 14.4 19.4 14.3 
95% CI 12.8–16.0 12.9–16.4 11.2–14.7 13.4–19.1 11.8–18.7 9.7–20.5 8.5–22.8 8.7–37.1 13.5–15.2 
Notes 
1. Crude rate is the number of women with DCIS detected per 10,000 women screened; age-standardised (AS) rate is the number of women 
with DCIS detected per 10,000 women screened and age-standardised to the population of women attending a BreastScreen Australia 
service in 2008; rates based on numbers less than 20 should be interpreted with caution; 95% CI are 95% confidence intervals. 
2. State and territory differences, along with the size of the 95% confidence intervals (particularly in the smaller states and territories), need to 
be taken into consideration when interpreting DCIS detection results.  
3. In some states and territories, the age-standardised rates vary considerably from the crude rates. 
4. A small number of women may be screened in one jurisdiction but have their DCIS detected in another. 
Source: AIHW analysis of BreastScreen Australia data. 
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A6a Interval cancers 
Box A1: Different policies across state and territory BreastScreen programs 
affects interval cancer detection rates 
Please note that differences in state and territory policies for managing women with 
symptoms may affect interval cancer rates.  
For example, in some jurisdictions, women with a negative screening mammogram but who 
have symptoms are referred for diagnostic follow-up outside BreastScreen Australia, rather 
than being recalled for assessment within BreastScreen Australia; any cancers found in 
these women will be counted as interval cancers, leading to a higher apparent interval 
cancer rate. Conversely, states and territories that do recall women to assessment if they 
have symptoms (even in the face of a negative screening mammogram) may have lower 
apparent interval cancer rates. This affects the comparability of this indicator between 
jurisdictions. 
Table A6.1: Interval cancer rate for women aged 50–69, screened in index years 2008, 2009 and 2010, 
by state and territory, first and subsequent screening rounds, 0–12 months follow-up 
 NSW Vic Qld WA SA Tas ACT NT Australia 
First screening round 
AS rate  7.0 3.9 6.8 3.3 6.6 4.6 1.7 3.0 5.9 
95% CI 5.0–9.5 2.7–5.5 4.0–10.5 0.7–7.8 1.2–15.1 0.9–13.4 0.0–9.2 0.1–16.6 4.7–7.2 
Subsequent screening rounds 
AS rate  7.0 5.0 6.0 6.0 5.9 5.9 7.2 6.7 6.1 
95% CI 6.4–7.8 4.4–5.8 5.3–6.9 4.9–7.2 4.7–7.2 4.0–8.5 4.4–11.1 2.5–14.6 5.8–6.5 
Note: Age-standardised (AS) rate is the number of interval cancers detected per 10,000 women-years, age-standardised to the population of 
women attending a BreastScreen Australia service in 2008; 95% CI are 95% confidence intervals. 
Source: AIHW analysis of BreastScreen Australia data. 
Table A6.2: Interval cancer rate for women aged 50–69, screened in index years 2008, 2009 and 2010, 
by state and territory, first and subsequent screening rounds, 13–24 months follow-up 
 NSW Vic Qld WA SA Tas ACT NT Australia 
First screening round 
AS rate  9.8 10.1 9.0 9.0 4.7 13.2 33.4 3.0 9.8 
95% CI 7.3–12.9 6.8–14.2 5.7–13.2 4.5–15.1 2.5–8.0 3.5–31.2 4.5–87.2 0.1–16.9 8.2–11.6 
Subsequent screening rounds 
AS rate  10.8 13.5 12.0 10.3 13.9 14.2 15.6 13.5 12.1 
95% CI 9.9–11.7 12.4–14.7 11.0–13.2 8.8–11.9 12.0–16.0 10.9–18.2 10.9–21.6 7.0–23.6 11.6–12.6 
Note: Age-standardised (AS) rate is the number of interval cancers detected per 10,000 women-years, age-standardised to the population of 
women attending a BreastScreen Australia service in 2008; 95% CI are 95% confidence intervals. 
Source: AIHW analysis of BreastScreen Australia data. 
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Table A6.3: Interval cancer rate for women screened in index years 2008, 2009 and 2010, by age, all 
screening rounds, 0–12 months and 13–24 months follow-up 
Time since screen (months) 
 Age group (years) 
 40–49 50–59 60–69 70+ 
0–12 Number  284 670 561 142 
 Crude rate  8.2 6.0 6.2 7.4 
13–24 Number  388 1,173 1,118 287 
 Crude rate  11.9 11.0 13.1 15.8 
Note: Crude rate is the number of interval cancers detected per 10,000 women-years. 
Source: AIHW analysis of BreastScreen Australia data. 
Table A6.4: Interval cancer rate for women aged 50–69, screened in index years 2008, 2009 and 2010, 
by state and territory, first and subsequent screening rounds, 0–24 months follow-up 
 NSW Vic Qld WA SA Tas ACT NT Australia 
First screening round        
AS rate  8.3 7.0 7.9 6.1 5.7 8.6 16.4 3.0 7.8 
95% CI 6.7–10.2 5.2–9.1 5.7–10.6 3.4–9.6 2.5–10.0 3.4–17.2 2.6–40.7 0.4–10.8 6.8–8.9 
Subsequent screening rounds 
AS rate  8.9 9.3 9.0 8.0 9.7 9.7 11.1 10.1 9.0 
95% CI 8.3–9.4 8.6–9.9 8.4–9.7 7.1–9.0 8.6–10.9 7.8–11.9 8.3–14.4 6.0–15.9 8.7–9.4 
Note: Age-standardised (AS) rate is the number of interval cancers detected per 10,000 women-years, age-standardised to the population of 
women attending a BreastScreen Australia service in 2008; 95% CI are 95% confidence intervals. 
Source: AIHW analysis of BreastScreen Australia data. 
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A6b Program sensitivity 
Table A6.5: Program sensitivity for women aged 50–69, screened in index years 2008, 2009 and 2010, 
by state and territory, first and subsequent screening rounds, 0–12 months follow-up 
 NSW Vic Qld WA SA Tas ACT NT Australia 
First screening round        
AS rate 92.3 93.9 92.9 96.2 91.4 94.8 98.5 96.5 93.2 
95% CI 84.7–
100.0 
82.0–
100.0 
82.5–
100.0 
79.8–
100.0 
71.4–
100.0 
68.4–
100.0 
70.6–
100.0 
51.5–
100.0 
88.3– 
98.2 
Subsequent screening rounds 
AS rates 86.2 89.8 89.0 87.7 87.9 86.4 92.0 89.2 88.1 
95% CI 82.8–
89.8 
85.7– 
94.0 
85.1– 
93.2 
81.7– 
93.9 
81.1– 
95.0 
74.9– 
99.1 
79.7–
100.0 
65.8–
100.0 
86.2– 
90.1 
Note: Age-standardised (AS) rate is the number of screen-detected cancers as a percentage of all cancers (screen-detected and interval cancers), 
age-standardised to the population of women attending a BreastScreen Australia service in 2008; 95% CI are 95% confidence intervals. 
Source: AIHW analysis of BreastScreen Australia data. 
Table A6.6: Program sensitivity for women aged 50–69, screened in index years 2008, 2009 and 2010 , 
by state and territory, first and subsequent screening rounds, 0–24 months follow-up 
 NSW Vic Qld WA SA Tas ACT NT Australia 
First screening round        
AS rates 84.0 83.1 91.0 90.6 84.7 85.4 87.1 93.4 85.6 
95%CI 77.0–
91.5 
72.2–
94.8 
80.9–
100.0 
74.9–
100.0 
65.6–
100.0 
61.4–
100.0 
62.6–
100.0 
49.2–
100.0 
81.1–
90.3 
Subsequent screening rounds 
AS rates 72.0 70.7 80.8 82.7 69.9 69.5 79.4 73.9 74.5 
95%CI 69.2–
75.0 
67.5–
74.0 
77.2–
84.5 
77.1–
88.6 
64.6– 
75.5 
60.3– 
79.5 
69.0– 
90.9 
54.4– 
98.1 
72.9–
76.2 
Note: Age-standardised (AS) rate is the number of screen-detected cancers as a percentage of all cancers (screen-detected and interval cancers), 
age-standardised to the population of women attending a BreastScreen Australia service in 2008; 95% CI are 95% confidence intervals. 
Source: AIHW analysis of BreastScreen Australia data. 
Table A6.7: Program sensitivity for women screened in index years 2008, 2009 and 2010, all 
screening rounds, by age, 0–12 months and 0–24 months follow-up 
Time since screen (months) 
 Age group (years) 
 40–49 50–59 60–69 70+ 
0–12 Crude rate  79.0 87.3 91.1 92.9 
0–24 Crude rate  67.0 73.9 79.0 83.1 
Note: Crude rate is the number of interval cancers detected per 10,000 women-years. 
Source: AIHW analysis of BreastScreen Australia data. 
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A7a Invasive breast cancer incidence 
Table A7.1: Incidence of invasive breast cancer, 1982 to 2011 
Year of diagnosis Women aged 50–69 Women of all ages 
 Number of new cases of 
invasive breast cancer 
AS rate Number of new cases of 
invasive breast cancer 
AS rate 
1982 2,446 174.7 5,307 81.0 
1983 2,344 167.4 5,370 80.7 
1984 2,529 179.2 5,712 83.6 
1985 2,588 180.6 5,916 84.3 
1986 2,639 184.5 6,087 85.2 
1987 2,887 197.2 6,695 91.2 
1988 2,882 194.4 6,726 89.5 
1989 3,122 208.1 7,172 93.5 
1990 3,153 209.2 7,424 94.9 
1991 3,500 230.0 8,036 100.3 
1992 3,394 221.9 8,004 98.0 
1993 3,868 250.7 8,774 105.3 
1994 4,470 283.8 9,748 114.5 
1995 4,546 286.3 10,058 116.1 
1996 4,381 270.2 9,744 109.8 
1997 4,673 279.0 10,202 112.1 
1998 5,000 289.9 10,736 115.3 
1999 5,121 288.6 10,661 111.9 
2000 5,457 298.4 11,394 116.8 
2001 5,801 307.5 11,835 118.4 
2002 5,982 307.1 12,081 118.2 
2003 5,806 288.6 11,874 113.6 
2004 6,047 292.0 12,213 114.5 
2005 6,043 283.3 12,261 112.7 
2006 6,412 291.4 12,694 114.2 
2007 6,322 278.5 12,643 111.0 
2008 6961 298.1 13,615 117.0 
2009 7,027 291.3 13,756 115.3 
2010 7,478 301.2 14,256 117.0 
2011 7,499 292.8 14,465 116.0 
Note: Age-standardised (AS) rate is the number of new cases of breast cancer per 100,000 women, age-standardised to the Australian  
population at 30 June 2001. 
Source: AIHW Australian Cancer Database 2011. 
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Table A7.2: Incidence of invasive breast cancer, by age, 2011 
 Age group (years) 
 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+ 
New cases 984 1,547 1,833 1,766 2,125 1,776 1,176 868 804 820 
Crude rate 122.9 198.9 242.9 262.0 345.6 370.0 317.5 289.4 317.1 310.0 
Note: Crude rate is the number of new cases of breast cancer per 100,000 women. 
Source: AIHW Australian Cancer Database 2011. 
Table A7.3: Incidence of invasive breast cancer, by age and histology group, 2009 
Type of breast cancer 40–49 50–59 60–69 70+ 
Invasive ductal carcinoma 2,002 2,766 2,869 2,539 
Invasive lobular carcinoma 214 335 437 403 
Medullar carcinoma and atypical medullary carcinoma 21 13 15 7 
Tubular carcinoma and invasive cribriform carcinoma 33 72 74 35 
Mucinous carcinoma 27 35 60 148 
Invasive papillary carcinoma 24 30 42 49 
Inflammatory carcinoma 7 4 7 3 
Mesenchymal 1 4 3 5 
Other - specified 35 41 54 77 
Unspecified 55 75 90 303 
Note: One woman was unale to be allocated to a group and so does not appear in this table. 
Source: AIHW Australian Cancer Database 2011. 
Table A7.4: Incidence of invasive breast cancer by state and territory, women aged 50–69, 2005–2009 
 NSW Vic  Qld WA SA Tas ACT NT Australia  
New cases 10,934 7,857 6,602 3,059 2,703 840 592 178 32,765 
AS rate 292.4 281.1 298.4 274.1 292.4 279.2 334.9 213.3 288.7 
95% CI 291.3–
293.4 
279.8–
282.3 
296.9–
299.8 
272.2–
276.0 
290.2–
294.6 
275.5–
283.1 
329.7–
340.4 
207.2–
220.1 
288.1–
289.3 
Note: Age-standardised (AS) rate is the number of new cases of breast cancers per 100,000 women age-standardised to the Australian population 
at 30 June 2001. 95% CI are 95% confidence intervals.  
Source: AIHW Australian Cancer Database 2011. 
Table A7.5: Incidence of invasive breast cancer by remoteness area, women aged 50–69, 2005–2009 
 Major cities Inner regional Outer regional Remote Very remote Australia 
New cases  21,942 7,190 3,095 396 123 32,765 
AS rate 286.4 304.9 276.3 278.7 182.7 288.7 
95% CI 285.7–287.1 303.5–306.3 274.4–278.3 273.4–284.4 176.5–189.6 288.1–289.3 
Notes  
1. Age-standardised (AS) rate is the number of new cases of breast cancers per 100,000 women age-standardised to the Australian 
population at 30 June 2001. 95% CI are 95% confidence intervals. 
2. Remoteness areas were assigned using the woman’s residential postcode according to the Australian Standard Geographical Classification 
for 2006. Not all postcodes can be assigned to a remoteness area, therefore categories do not add exactly to the total for Australia. 
Source: AIHW Australian Cancer Database 2011. 
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Table A7.6: Incidence of invasive breast cancer by socioeconomic status, women aged 50–69, 
2006–2009 
 1(lowest) 2 3 4 5 (highest) Australia 
New cases  5,113 5,531 5,054 5,166 5,835 26,722 
AS rate 273.1 285.0 284.8 297.4 308.1 289.9 
95% CI 271.6–274.6 283.5–286.5 283.3–286.4 295.8–299.0 306.6–309.7 289.2–290.6 
Notes 
1. Age-standardised (AS) rate is the number of new cases of breast cancers per 100,000 women age-standardised to the Australian 
population at 30 June 2001. 95% CI are 95% confidence intervals. 
2. Socioeconomic status was assigned using the woman’s residential postcode according to the Socioeconomic Index for Areas (SEIFA) Index 
of Relative Socioeconomic Disadvantage for 2006; 1 (lowest socioeconomic group) corresponds to the most disadvantaged socioeconomic 
status and 5 (highest socioeconomic group) to the least disadvantaged socioeconomic status. Not all postcodes could be assigned to a 
socioeconomic category, therefore, categories do not add exactly to the total for Australia. 
Source: AIHW Australian Cancer Database 2011. 
Table A7.7: Incidence of breast cancer (New South Wales, Queensland, Western Australia and the 
Northern Territory) by Indigenous status, women aged 50–69, 2005–2009 
 Indigenous(a) Non-Indigenous(a) Total(a) 
New cases 255 19,002 20,773 
Crude rate 195.2 272.8 292.7 
AS rate  202.9 270.6 290.5 
95% CI 198.1–208.2 269.8–270.6 289.7–290.5 
(a)  Indigenous, Non-Indigenous and Total are for New South Wales, Queensland, Western Australia and the Northern Territory only. Data from 
these jurisdictions were considered to have adequate levels of Indigenous identification in cancer registration data at the time this report 
was prepared. Total includes women in the ‘not stated’ category. 
Notes 
1. Some states and territories use an imputation method for determining Indigenous cancers that may lead to differences between these data 
and those shown in jurisdictional cancer incidence reports. 
2. Crude rate is the number of new cases of breast cancer per 100,000 women; age-standardised (AS) rates are the number of breast cancers 
detected per 100,000 women directly age-standardised to the Australian population at 30 June 2001. 95% CI are 95% confidence intervals. 
Source: AIHW Australian Cancer Database 2011. 
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A7b Ductal carcinoma in situ (DCIS) incidence 
Table A7.8: Incidence of DCIS, 1996 to 2009 
Year of diagnosis Women aged 50–69 Women of all ages 
 Number of new 
cases of DCIS 
AS rate Number of new 
cases of DCIS 
AS rate 
1996 501 30.9 912 10.4 
1997 584 34.8 1,041 11.6 
1998 660 38.1 1,163 12.6 
1999 701 39.3 1,179 12.5 
2000 783 42.6 1,317 13.6 
2001 891 46.9 1,435 14.5 
2002 835 42.6 1,379 13.6 
2003 869 43.0 1,436 13.7 
2004 928 44.6 1,533 14.4 
2005 971 45.2 1,562 14.3 
2006 963 43.5 1,513 13.6 
2007 998 43.7 1,613 14.1 
2008 1,109 47.0 1,732 14.8 
2009 1,152 48.0 1,803 15.2 
Note: Age-standardised (AS) rate is the number of new cases of DCIS per 100,000 women age-standardised to the Australian population at 30 
June 2001. 
Source: AIHW Australian Cancer Database 2011. 
Table A7.9: Incidence of DCIS, by age, 2009 
 Age group (years) 
 40–49 50–59 60–69 70+ 
New cases 320 597 555 268 
Crude rate 20.7 43.6 54.8 23.6 
Note: Crude rate is the number of new cases of DCIS per 100,000 women. 
Source: AIHW Australian Cancer Database 2011. 
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A8 Mortality 
Table A8.1: Mortality from breast cancer, 1982 to 2012 
Year of death Women aged 50–69 Women of all ages 
 Number of deaths AS rate Number of deaths AS rate 
1982 933 66.9 1,987 30.4 
1983 992 69.9 2,040 30.2 
1984 978 69.2 2,166 31.6 
1985 991 68.8 2,196 31.2 
1986 970 66.6 2,165 29.9 
1987 1,010 69.4 2,293 31.1 
1988 1,043 69.6 2,361 31.2 
1989 1,050 69.0 2,449 31.6 
1990 1,056 68.7 2,422 30.6 
1991 1,049 68.2 2,526 31.3 
1992 949 61.2 2,429 29.4 
1993 1,083 69.0 2,611 30.8 
1994 1,059 66.9 2,669 30.9 
1995 1,083 66.7 2,635 29.7 
1996 1,035 62.9 2,620 28.8 
1997 1,030 60.9 2,604 27.9 
1998 986 56.9 2,541 26.5 
1999 997 56.2 2,512 25.6 
2000 953 52.0 2,521 24.9 
2001 994 52.6 2,594 25.0 
2002 1,108 56.9 2,681 25.2 
2003 1,099 54.6 2,710 24.9 
2004 1,088 52.3 2,665 24.0 
2005 1,114 52.1 2,710 23.8 
2006 1,058 47.9 2,624 22.4 
2007 1,099 48.1 2,722 22.6 
2008 1,106 47.0 2,746 22.3 
2009 1125 46.5 2,785 22.2 
2010 1,093 43.6 2,837 21.7 
2011 1,139 44.0 2,900 21.8 
2012 1,126 42.4 2,795 20.6 
Notes 
1.  Deaths from 1982 to 2011 were derived by year of death; deaths in 2012 were derived by year of registration of death. Deaths registered in 
2010 and earlier are based on the final version of cause-of-death data; deaths registered in 2011 and 2012 are based on revised and 
preliminary versions, respectively, and are subject to further revision by the ABS. 
2.  Age-standardised (AS) rate is number of deaths from breast cancer per 100,000 women age-standardised to the Australian population at 30 
June 2001. 
Source: AIHW National Mortality Database. 
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Table A8.2: Mortality from breast cancer, by age, 2012 
 Age group (years) 
 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+ 
Deaths 77 169 228 275 296 327 316 256 307 484 
Crude rate 9.3 21.9 29.6 39.8 48.1 63.4 82.2 83.8 121.3 177.0 
Notes 
1. Deaths in 2012 were derived using year of registration. Deaths registered in 2012 are based on the preliminary version of cause-of-death 
data and are subject to further revision by the ABS. 
2. Crude rate is the number of deaths from breast cancer per 100,000 women. 
Source: AIHW National Mortality Database. 
Table A8.3: Mortality from breast cancer by state and territory, 2008–2012 
 NSW Vic Qld WA SA Tas ACT NT Australia 
50–69 years          
Deaths  1,832 1,388 1,083 515 497 163 78 33 5,589 
AS rate  44.6 45.1 43.7 41.4 49.6 49.7 40.3 37.1 44.6 
95% CI 44.2–45.0 44.7–45.6 43.2–44.2 40.7–42.1 48.7–50.5 48.3–51.3 38.7–42.3 34.8–40.1 44.4–44.9 
All ages          
Deaths  4,734 3,666 2,533 1,278 1,206 390 191 65 14,063 
AS rate  21.8 22.4 20.8 20.7 22.2 23.3 21.4 20.5 21.7 
95% CI 21.1–22.6 21.5–23.2 19.9–21.7 19.5–22.0 20.6–24.0 20.4–26.5 18.6–24.6 17.7–23.7 21.3–22.1 
Notes 
1. Deaths from 2008 to 2011 were derived by year of death; deaths in 2012 were derived by year of registration of death. Deaths registered in 
2010 and earlier are based on the final version of cause-of-death data; deaths registered in 2011 and 2012 are based on revised and 
preliminary versions, respectively, and are subject to further revision by the ABS.  
2.  Age-standardised (AS) rate is the number of deaths from breast cancer per 100,000 women, age-standardised to the Australian population 
at 30 June 2001; 95% CI are 95% confidence intervals. 
Source: AIHW National Mortality Database. 
Table A8.4: Mortality from breast cancer, by remoteness area, 2008–2012 
 Major cities Inner regional Outer regional Remote Very remote Australia 
50–69 years       
Deaths 3,735 1,198 538 76 28 5,589 
AS rate 44.3 45.7 43.7 49.6 38.3 44.6 
95% CI 44.0–44.6 45.2–46.3 43.0–44.4 47.5–52.0 35.7–41.6 44.4–44.9 
All ages       
Deaths 9,519 3,017 1,299 140 56 14,063 
AS rate 21.5 22.5 21.7 20.4 18.1 21.7 
95% CI 21.0–21.9 21.4–23.6 20.2–23.1 17.3–23.8 15.0–21.8 21.3–22.1 
Notes 
1. Women were allocated to a remoteness area using residential statistical local area (SLA) according to the Australian Standard Geographic 
Classification for 2008–2010 and using residential statistical area level 2 (SA2) according to the Australian Statistical Geography Standard 
for 2011–2012. 
2.  Deaths from 2008 to 2011 were derived by year of death; deaths in 2012 were derived by year of registration of death. Deaths registered in 
2010 and earlier are based on the final version of cause-of-death data; deaths registered in 2011 and 2012 are based on revised and 
preliminary versions, respectively, and are subject to further revision by the ABS. 
3. Age-standardised (AS) rate is the number of deaths from breast cancer per 100,000 women age-standardised to the Australian population 
at 30 June 2001; 95% CI are 95% confidence intervals. 
Source: AIHW National Mortality Database. 
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Table A8.5: Mortality from breast cancer (New South Wales, Queensland, Western Australia, South 
Australia and the Northern Territory) by Indigenous status, women aged 50–69 and women of all 
ages, 2008–2012 
 Indigenous(a) Non-Indigenous(a) Total(a) 
50–69 years    
Deaths 75 3,847 3,960 
Crude rate 45.7 44.9 45.3 
AS rate 48.1 43.9 44.4 
95% CI 46.0–50.5 43.6–43.9 44.1–44.4 
All ages    
Deaths 149 9,582 9,816 
Crude rate 10.2 25.3 25.0 
AS rate 24.1 21.7 21.9 
95% CI 22.5–25.9 21.2–22.2 21.4–22.4 
(a)  Indigenous, Non-Indigenous and Total are for New South Wales, Queensland, Western Australia, South Australia and the Northern Territory 
only; data from these jurisdictions were considered to have adequate levels of Indigenous identification in cancer mortality data at the time 
this report was prepared. Total includes women in the ‘not stated’ category.  
Notes 
1. Crude rate is the number of deaths from breast cancer per 100,000 women; age-standardised (AS) rate is the number of deaths from breast 
cancer per 100,000 women directly age-standardised to the Australian population at 30 June 2001; 95% CI are 95% confidence intervals. 
2.  Deaths from 2008 to 2011 were derived by year of death; deaths in 2012 were derived by year of registration of death. Deaths registered in 
2010 and earlier are based on the final version of cause-of-death data; deaths registered in 2011 and 2012 are based on revised and 
preliminary versions, respectively, and are subject to further revision by the ABS. 
Source: AIHW National Mortality Database. 
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Appendix B: BreastScreen Australia 
information 
Australia’s national breast cancer screening program was established in 1991 as the National 
Program for the Early Detection of Breast Cancer. This program is now known as 
BreastScreen Australia, and is a joint program of the Australian and state and territory 
governments. BreastScreen Australia aims to reduce mortality and morbidity from breast 
cancer. 
BreastScreen Australia provides free biennial breast cancer screening to women through 
dedicated screening and assessment services. Women have a screening mammogram 
performed at a screening unit (which may be fixed, relocatable or mobile). Women whose 
images are suspicious for breast cancer are recalled for further investigation by a 
multidisciplinary team at an assessment centre. Further investigation may include clinical 
examination, mammography, ultrasound and biopsy procedures. Most women who are 
recalled for assessment are found not to have breast cancer. 
Box B1: Objectives of BreastScreen Australia 
The objectives of the BreastScreen Australia program are to: 
1. Reduce the mortality and morbidity attributable to breast cancer. 
2. Maximise early detection of breast cancer in the target population. 
3. Maximise the proportion of women in the target population who are screened every 
two years. 
4. Provide high quality services that are equitable, acceptable and appropriate to the 
needs of the population and equally accessible to all women in the target age group. 
5. Provide screening and assessment services in accredited Screening and Assessment 
Services as part of the BreastScreen Australia program. 
6. Provide high standards of program management, service delivery, monitoring, 
evaluation and accountability. 
Source: BreastScreen Australia 2014. 
 
Box B2: All BreastScreen services now use digital mammography 
Digital mammography is a technique for recording breast x-ray images in computer code 
instead of on x-ray film, as with conventional film mammography. Digital mammography 
is as accurate as film mammography in screening asymptomatic women for breast cancer. 
Advantages of digital mammography include increased efficiencies, improved working 
environment for radiographers, less physical storage requirements, and reduced need for 
radiologists to be on site to read mammograms. 
In 2009, it was announced that $120 million would be provided over 4 years to ensure 
BreastScreen Australia would be fully digital by June 2013.  
All BreastScreen services now use digital mammography. 
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Box B3: National policy features of BreastScreen Australia 
Services accredited under BreastScreen Australia are expected to operate according to the 
national accreditation standards of BreastScreen Australia along with the national policy 
features and protocols detailed below.  
1: Access and participation 
1) Appropriate levels of access and participation in the target and eligible populations: 
a) women are selected for screening on the basis of age alone. That is, women 40 years of 
age and above are eligible to participate and recruitment strategies are targeted at women 
aged 50–74 years 
b) the screening interval is every two years 
c) screening is provided at minimal or no cost to the women, and free of charge to eligible 
women who would not attend if there were a charge 
d) patterns of participation are representative of the socioeconomic, ethnic and cultural 
profiles of the target population. 
2: Cancer detection 
2) Breast cancer detection is maximised in the target population and harm is minimised: 
a) screening employs mammography as the primary screening method 
b) all women are screened with two view mammography. Reasons for any variation from 
this policy are documented  
c) all mammograms are taken by a mammographic technologist or radiographer 
appropriately trained in screening mammography 
d) all mammographic images are read and reported independently, in a blind relationship, 
by two or more readers, at least one of whom shall be a radiologist 
e) all mammography results are combined into a single recommendation, which indicates 
whether or not further assessment for the presence of breast cancer is required.  
3: Assessment 
3) Assessment and diagnosis of breast cancer is appropriate, safe and effective:  
a) a comprehensive approach is employed in the assessment of breast abnormalities 
b) a multidisciplinary team is involved in the assessment of women recalled from screening  
c) the pre-operative diagnosis of breast cancer is maximised, and recommendations for 
surgery for benign lesions are minimised 
d) the outcomes for all women recommended for surgery are collected, reviewed and 
utilised in continuing professional education for members of the multidisciplinary team 
e) women’s general practitioners are kept informed of the results of screening and 
assessment, unless a woman directs otherwise.  
4: Timeliness 
4) Screening and assessment services are provided to women in a timely and efficient 
manner:  
a) women have timely access to screening 
b) the time from screening to assessment is minimised 
c) the results of screening and assessment are provided promptly and directly to the woman 
concerned in ways which are sensitive to her possible anxiety.  
(continued) 
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Box B3 (continued): National policy features of BreastScreen Australia 
5: Data management and information systems  
5) Effective data and information management systems:  
a) data are collected, stored and managed using secure, quality, contemporary data 
management and communication systems that comply with relevant state and national 
standards, and that enable valid, reliable system and service performance analysis and 
evaluation 
b) data are used for strategic purposes, quality improvement of services and for clinical and 
service management 
c) data are collected in line with the requirements of the BreastScreen Australia Data 
Dictionary 
d) data are to be submitted annually to the Australian Institute of Health and Welfare, for 
use in a national program monitoring report, and annual performance data reports for 
review by the National Quality Management Committee. 
6: Client focus 
6) Services are of high quality and client focused: 
a) high quality information is provided to inform women, and women feel appropriately 
engaged and supported 
b) screening services are provided in a manner which is acceptable to women in accessible, 
non-threatening and comfortable environments 
c) women and health care providers are given comprehensive and easily understood 
information about the Program, from screening up to and including diagnosis of breast 
cancer 
d) counselling and information are an integral part of the Program 
e) women are advised of the benefits and risks of mammography 
f) women are provided with written information and actively involved in decisions about 
their management, particularly in relation to further assessment and treatment.  
7: Governance and management 
7) Effective structures and processes are in place to ensure high quality governance and 
management: 
a) screening and assessment are carried out at BreastScreen Australia accredited services 
b) key stakeholders and stakeholder groups participate in the monitoring and management 
of the Program.  
Performance indicators 
The performance of a population-based cancer screening program such as BreastScreen 
Australia needs to be assessed as it relates to the underlying aims of the program. At the 
national level, this is achieved by reporting data against a series of performance indicators to 
allow screening outcomes to be monitored, and positive and negative trends identified early.  
BreastScreen Australia has been monitored since 1996–1997 using performance indicators 
developed and endorsed by the former National Screening Information Advisory Group and 
by jurisdictional BreastScreen programs. These national performance indicators represent 
key measures of the progress BreastScreen Australia is making towards reducing morbidity 
and mortality from breast cancer; they are listed in Table B1. 
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Table B1: Performance indicators for BreastScreen Australia 
Performance indicators 
1 Participation The percentage of women aged 50–69 who have a screening 
mammogram through BreastScreen Australia in a 2-year period 
2 Rescreening The proportion of women screened who return for a rescreen within 
27 months 
3 Recall to assessment  The proportion of women screened who are recalled for further 
investigation 
4 Invasive breast cancer detection The number of women with invasive breast cancer detected through 
BreastScreen Australia 
5 Ductal carcinoma in situ detection  The number of women with DCIS detected through BreastScreen 
Australia 
6 Sensitivity The ability of screening mammography to successfully detect cancers 
6a Interval cancers  
6b Program sensitivity  
7 Incidence The number of new cases of invasive breast cancer or DCIS  
7a Invasive breast cancer incidence  
7b Ductal carcinoma in situ incidence  
8 Mortality The number of deaths from invasive breast cancer 
Note: Further details and definitions of performance indicators are available in previous BreastScreen Australia monitoring reports and in the 
BreastScreen Australia data dictionary: version 1.1 (AIHW 2015b). 
Source: BreastScreen Australia data dictionary: version 1.1 (AIHW 2015b). 
National Accreditation Standards (NAS) Measures 
Provision of a high-quality service to women is of great importance to BreastScreen 
Australia. For this reason, services accredited under BreastScreen Australia are expected to 
operate according to the National Accreditation Standards (NAS) of BreastScreen Australia, 
along with national policy features and protocols. The accreditation system, of which the 
NAS are an integral part, intends to drive continuous quality improvement in the delivery of 
breast screening services to ensure women receive safe, effective and high-quality care. 
The BreastScreen Australia NAS have been developed to ensure that all women receive 
breast screening services which are of a consistently high quality, regardless of where they 
attend for screening or assessment. 
A number of NAS are consistent with the performance indicators in this report. For this 
reason, where appropriate, the data in this report are benchmarked against the NAS. These 
benchmarks are useful in helping to interpret the data presented, although in considering 
how these national data compare with the NAS, it should be noted that the NAS were not 
designed to be used as standards for the BreastScreen Australia performance indicators. 
NAS Measures that relate to these data, along with data analysed by the AIHW, appear in 
tables 3.1, 3.4 and 3.7 in this report. 
Contact details and online resources for BreastScreen Australia components are provided in 
Table B2. 
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Table B2: Contacts and links for the state, territory and Australian government components of 
BreastScreen Australia 
BreastScreen New South Wales 
Tel: (02) 8374 5777 
Fax: (02) 8374 5699 
Email: information@cancerinstitute.org.au 
<www.bsnsw.org.au> 
 
BreastScreen Victoria 
Tel: (03) 9660 6888 
Fax: (03) 9662 3881 
Email: info@BreastScreen.org.au 
<www.BreastScreen.org.au> 
 
BreastScreen Queensland 
Tel: (07) 3328 9467 
Fax: (07) 3328 9487 
Email: cssb@health.gov.au 
<www.health.qld.gov.au/breastscreen> 
 
BreastScreen Western Australia 
Tel: (08) 9323 6700 
Fax: (08) 9323 6799 
Email: BreastScreenwa@health.wa.gov.au 
<www.BreastScreen.health.wa.gov.au> 
 
BreastScreen South Australia 
Tel: (08) 8274 7100 
Fax: (08) 8373 4395 
Email: HealthBSSAEnquiries@sa.gov.au 
<www.breastscreensa.sa.gov.au> 
BreastScreen Tasmania 
Tel: (03) 6216 4300 
Fax: (03) 6216 4326 
Email: canscreen@dhhs.tas.gov.au 
<www.dhhs.tas.gov.au/cancerscreening/information_ 
about_breast_screening> 
BreastScreen ACT 
Tel: (02) 6205 4444 
Fax: (02) 6205 1394 
Email: BreastScreen@act.gov.au 
<www.health.act.gov.au/our-services/women-youth-and-
children/breastscreen> 
 
BreastScreen NT 
Tel: (08) 8922 6449 
Fax: (08) 8922 6440 
Email: wcpp.ths@nt.gov.au 
<www.health.nt.gov.au/Womens_Health/Breast_Screen_NT/in
dex.aspx> 
 
Australian Government Department of Health  
Email: cancerscreening@health.gov.au 
 
<http://www.cancerscreening.gov.au/internet/screening/publis
hing.nsf/Content/breast-screening-1> 
AIHW  
Email: screening@aihw.gov.au <http://www.aihw.gov.au/cancer/screening/breast> 
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Appendix C: Data sources 
Data used in this report are derived from multiple sources and are summarised in Table C1. 
Table C1: Data sources for BreastScreen Australia monitoring report 2012–2013 
Data used to monitor BreastScreen Australia Data source 
Monitoring BreastScreen Australia using BreastScreen data 
Performance Indicator 1 Participation State and territory BreastScreen registers, ABS population data 
Performance Indicator 2 Rescreening State and territory BreastScreen registers 
Performance Indicator 3 Recall to assessment State and territory BreastScreen registers 
Performance Indicator 4 Invasive breast cancer detection State and territory BreastScreen registers 
Performance Indicator 5 DCIS detection State and territory BreastScreen registers 
Performance Indicator 6 Sensitivity State and territory BreastScreen registers 
Monitoring BreastScreen Australia using AIHW data 
Performance Indicator 7 Incidence AIHW Australian Cancer Database 2011; ABS population data 
Performance Indicator 8 Mortality AIHW National Mortality Database; ABS population data 
Monitoring other aspects of BreastScreen Australia 
Expenditure on BreastScreen Australia AIHW Health Expenditure Database 
State and territory BreastScreen registers 
Data for the performance indicators participation, rescreening, recall to assessment, invasive 
breast cancer detection, ductal carcinoma in situ (DCIS) detection, and sensitivity are sourced 
from the BreastScreen register in each state and territory according to definitions and data 
specifications in the BreastScreen Australia data dictionary version 1.1 (AIHW 2015b). These 
data are compiled into national figures by the Australian Institute of Health and Welfare 
(AIHW) to allow national monitoring of BreastScreen Australia.  
The Data Quality Statement for BreastScreen Australia data appears in Appendix D, and can 
also be found on the AIHW website at 
<http://meteor.aihw.gov.au/content/index.phtml/itemId/569662>. 
AIHW Australian Cancer Database 
All forms of cancer, except basal and squamous cell carcinomas of the skin, are notifiable 
diseases in each Australian state and territory. This means there is legislation in each 
jurisdiction that requires hospitals, pathology laboratories and various other institutions to 
report all cases of cancer to their central cancer registry. An agreed subset of the data 
collected by these cancer registries is supplied annually to the AIHW, where they are 
compiled into the Australian Cancer Database (ACD). The ACD currently contains data on 
all cases of cancer diagnosed from 1982 to 2009 for all states and territories, and for 2010 and 
2011 for all except New South Wales and the Australian Capital Territory. 
The 2010 and 2011 incidence data for New South Wales and the Australian Capital Territory 
were not available for inclusion in the 2011 version of the ACD. The development of the new 
NSW Cancer Registries system has resulted in a delay in processing incidence data for 2010 
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onwards and therefore the most recent NSW data available for inclusion in the ACD are for 
2009. Full details about this situation are given at: 
<http://www.cancerinstitute.org.au/data-and-statistics/accessing-our-data/availability-of-
nsw-central-cancer-registry-data>. As the coding of Australian Capital Territory cancer 
notifications is contracted to the NSW Cancer Registry, the most recent data available for the 
Australian Capital Territory are also for 2009.  
The 2010 and 2011 incidence data for New South Wales and the Australian Capital Territory 
were estimated by the AIHW. These estimates were combined with the actual data supplied 
by the other 6 state and territory cancer registries to form the 2011 ACD. The detailed 
methodology by which data for New South Wales and the Australian Capital Territory were 
estimated for 2010 and 2011 is available in Appendix F of Cancer in Australia: an overview 2014 
(AIHW 2014). 
Cancer reporting and registration is a dynamic process, and records in the state and territory 
cancer registries may be modified if new information is received. As a result, the number of 
cancer cases reported by the AIHW for any particular year may change slightly over time 
and may not always align with state and territory reporting for that same year. 
Data have been analysed using the year of diagnosis of cancer. This is a more accurate 
reflection of incidence during a particular year than the year of registration of cancer. 
The Data Quality Statement for the ACD 2011 can be found on the AIHW website at 
<http://meteor.aihw.gov.au/content/index.phtml/itemId/586979>. 
AIHW National Mortality Database 
The AIHW National Mortality Database (NMD) contains information provided by the 
Registries of Births, Deaths and Marriages and the National Coronial Information System 
(managed by the Victorian Department of Justice), and includes cause of death coded by the 
Australian Bureau of Statistics (ABS), for deaths from 1964 to 2012. Registration of deaths is 
the responsibility of the state and territory registrars of births, deaths and marriages. These 
data are then collated and coded by the ABS and are maintained at the AIHW in the NMD. 
In the NMD, the year of occurrence of the death, and the year in which the death was 
registered, are both provided. For the purposes of this report, actual mortality data are 
shown based on the year of occurrence of the death, except for the most recent year (2012) 
where the number of people whose death was registered is used. Previous investigation has 
shown that the year of death and its registration coincide for the most part. However, in 
some instances, deaths at the end of each calendar year may not be registered until the 
following year. Thus, year-of-death information for the latest available year is generally an 
underestimate of the actual number of deaths that occurred in that year. 
In this report, deaths registered in 2010 and earlier are based on the final version of cause-of-
death data; deaths registered in 2011 and 2012 are based on revised and preliminary 
versions, respectively, and are subject to further revision by the ABS. 
A statement on data quality relating to the AIHW NMD is available at the following ABS 
website: Quality declaration summary, Causes of death, 2012 (ABS cat. no. 3303.0) 
<http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/3303.0Quality+Declaration02012>. 
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ABS population data 
Throughout this report, population data were used to derive rates of participation in breast 
cancer screening, breast cancer incidence and breast cancer mortality. The population data 
were sourced from the ABS using the most up-to-date estimates available at the time of 
analysis. 
To derive its estimates of the resident populations, the ABS uses the 5-yearly Census of 
Population and Housing data and adjusts it as follows: 
• All respondents in the Census are placed in their state or territory, Statistical Local Area 
(SLA) and postcode of usual residence; overseas visitors are excluded. 
• An adjustment is made for persons missed in the Census. 
• Australians temporarily overseas on Census night are added to the usual residence 
Census count. 
Estimated resident populations are then updated each year from the Census data, using 
indicators of population change, such as births, deaths and net migration. More information 
is available from the ABS website at <www.abs.gov.au>. 
For the Indigenous comparisons in this report, the most recently released Indigenous 
experimental estimated resident populations as released by the ABS were used. Those 
estimates were based on the 2011 Census of Population and Housing. 
ABS population data for participation calculations 
Participation rates were calculated using the average of the estimated resident female 
population for the 2-year reporting period.  
Note that there is the potential for variation in published participation rates between the 
AIHW and state and territory reports because of different sources of estimated resident 
population data. 
ABS population data for incidence and mortality calculations 
Incidence and mortality rates were calculated using the estimated resident population for 
single-year calculations, and the aggregate of the estimated resident populations for the 5 
relevant years for 5-year calculations (or 4 years in the case of incidence for different groups 
of socioeconomic status). 
AIHW Disease Expenditure Database 
The AIHW Disease Expenditure Database contains estimates of expenditure by disease 
category, age group and sex for each of the following areas of expenditure: admitted patient 
hospital services, out-of-hospital medical services, prescription pharmaceuticals, 
optometrical and dental services, community mental health services and public health cancer 
screening. 
For more information on the AIHW Disease Expenditure Database, see Health system 
expenditure on cancer and other neoplasms in Australia: 2008–09 (AIHW 2013). 
The Data Quality Statement for the Disease Expenditure Database can be found on the 
AIHW website at <http://meteor.aihw.gov.au/content/index.phtml/itemId/512599>. 
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Appendix D: BreastScreen Australia 
2012–2013 Data Quality Statement 
Summary of key data quality issues 
• All states and territories maintain a population-based BreastScreen register which 
records the data collected during a woman’s contact with a BreastScreen service.  
• The Australian Institute of Health and Welfare (AIHW) compiles BreastScreen Australia 
data supplied from state and territory BreastScreen registers in order to monitor 
BreastScreen Australia annually at a national level.  
• State and territory BreastScreen registers change every day, adding new records and 
improving the quality of existing records as new information becomes available. 
BreastScreen Australia data may therefore change.  
Description  
BreastScreen Australia is Australia’s national, population-based breast cancer screening 
program and is a joint program of the Australian and state and territory governments.  
BreastScreen registers in each state and territory record data collected during a woman’s 
contact with a BreastScreen service. 
Each BreastScreen program supplies BreastScreen data annually to the AIHW. These data are 
compiled into the BreastScreen Australia database, held at the AIHW to enable national 
monitoring of BreastScreen Australia. 
Some BreastScreen data are supplied as aggregate data and therefore cannot be interrogated 
in more detail. 
The majority of screening mammography performed in Australia is through BreastScreen 
Australia. However, a relatively small amount of screening mammography occurs through 
services other than BreastScreen Australia, which are not within the scope of these data. 
Institutional environment  
The AIHW is a major national agency set up by the Australian Government under the 
Australian Institute of Health and Welfare Act 1987 (Cwlth) to provide reliable, regular and 
relevant information and statistics on Australia’s health and welfare. It is an independent 
corporate Commonwealth entity established in 1987, governed by a management Board, and 
accountable to the Australian Parliament through the Health portfolio. 
The AIHW aims to improve the health and wellbeing of Australians through better health 
and welfare information and statistics. It collects and reports information on a wide range of 
topics and issues, ranging from health and welfare expenditure, hospitals, disease and 
injury, and mental health, to ageing, homelessness, disability and child protection. 
The Institute also plays a role in developing and maintaining national metadata standards. 
This work contributes to improving the quality and consistency of national health and 
welfare statistics. The Institute works closely with governments and non-government 
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organisations to achieve greater adherence to these standards in administrative data 
collections to promote national consistency and comparability of data and reporting. 
One of the main functions of the AIHW is to work with the states and territories to improve 
the quality of administrative data and, where possible, to compile national data sets based on 
data from each jurisdiction, to analyse these data sets and disseminate information and 
statistics. 
The Australian Institute of Health and Welfare Act 1987, in conjunction with compliance to the 
Privacy Act 1988 (Cwlth), ensures that the data collections managed by the AIHW are kept 
securely and under the strictest conditions with respect to privacy and confidentiality. 
For further information, see the AIHW website <www.aihw.gov.au>. 
The AIHW has been receiving BreastScreen data since 1996. 
Timeliness  
BreastScreen data are available within about 6–12 months of activity (it can take up to 12 
months for final pathology results on all breast tissue samples to be received by BreastScreen 
registers.) The BreastScreen Australia database cannot be fully compiled until the final 
jurisdiction supplies its data. 
Participation data for the previous calendar year are supplied in July each year; rescreening 
and invasive breast cancer and ductal carcinoma in situ (DCIS) detection data for the 
previous calendar year are supplied July–December each year. (Rescreening and sensitivity 
data lag behind, as the specifications for these require a specified period of time to pass 
before they can be accurately calculated.) 
The current BreastScreen Australia database contains data on women who participated in 
BreastScreen Australia between 1996 and 2013. 
Accessibility  
BreastScreen Australia data are published annually in the BreastScreen Australia monitoring 
report available on the AIHW website <http://www.aihw.gov.au/breast-cancer-screening> 
where they can be downloaded without charge. Supplementary data tables presenting more 
detailed data accompany each report and these, too, are available on the AIHW website 
where they can be downloaded without charge. 
General enquiries about AIHW publications can be made to the Digital and Media 
Communications Unit on (02) 6244 1032 or via email to <info@aihw.gov.au>. 
Interpretability  
While many concepts in the BreastScreen Australia monitoring report are easy to interpret, 
other concepts and statistical calculations are more complex. All concepts are explained 
within the body of the report presenting these data, along with footnotes to provide further 
details and caveats. The appendixes provide additional detail on the data sources and 
classifications, and on the statistical methods used. 
 66 BreastScreen Australia monitoring report 2012–2013 
Relevance  
Breast cancer screening data are highly relevant for monitoring trends in breast screening 
participation and the detection of invasive breast cancer and DCIS, as well as other measures 
of program performance, such as recall rates and sensitivity measures. The data are used for 
many purposes by policy makers and researchers, but are supplied and analysed specifically 
to monitor and inform BreastScreen Australia. 
Accuracy 
All data provided by state and territory BreastScreen programs, once analysed, are supplied 
back to the jurisdictional BreastScreen programs for verification. 
Women attending a BreastScreen service are able to self-report Indigenous status; this 
database field is therefore considered to be of high quality. However, use of the ‘not stated’ 
category has changed substantially over time, which makes trend data difficult to interpret. 
State and territory BreastScreen databases change every day, and not just because new 
records are added; existing records are changed if new, more precise information becomes 
available or if typographical errors are discovered by routine data checking procedures. As a 
result, the number of women participating, as well as DCIS and invasive breast cancer cases 
reported by the AIHW for any particular year, may change slightly over time. Further, data 
published by a jurisdictional BreastScreen program at a certain point in time may differ 
slightly from what is published by the AIHW at a different time. 
Coherence  
BreastScreen data are reported and published annually by the AIHW.  
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Appendix E: Classifications 
Age 
The data in this report are stratified by the age of the woman at the time of the specified test 
(for screening data), at the time of diagnosis (for cancer incidence data) or at the time of 
death (for cancer mortality data). 
State or territory 
The state or territory reported is the one where screening took place (for the screening data), 
where the diagnosis was made (for the cancer incidence data) or the place of usual residence 
(for the cancer mortality data). 
Remoteness area 
The remoteness areas (RAs) divide Australia into broad geographical regions that share 
common characteristics of remoteness for statistical purposes. The remoteness structure 
divides each state and territory into several regions on the basis of their relative access to 
services. There are 6 classes of RA in the remoteness structure: Major cities, Inner regional, 
Outer regional, Remote Australia, Very remote and Migratory. The category Major cities includes 
Australia’s capital cities, except for Hobart and Darwin, which are classified as Inner regional. 
RAs are based on the Accessibility and Remoteness Index of Australia produced by the 
Australian Population and Migration Research Centre at the University of Adelaide. 
Remoteness area for participation calculations 
For participation calculations, women were allocated to a remoteness area using their 
residential postcode supplied at the time of screening. Caution is required when examining 
differences across remoteness areas. First, postcodes used to allocate women may not 
represent their location of residence. Second, because these are based on the 2011 Census, the 
accuracy of remoteness area classifications diminishes due to subsequent changes in 
demographics. Third, some postcodes (and hence some individual women) are unable to be 
allocated to a remoteness area.  
Remoteness area for incidence and mortality calculations 
Each unit record in the Australian Cancer Database (ACD) contains the 2006 Statistical Local 
Area (SLA) and 2011 Statistical Area Level 2 (SA2) but not the remoteness area. In order to 
calculate the cancer incidence rates by remoteness area, a correspondence was used to map 
the 2006 SLA to the 2006 RA. Similarly, the cancer mortality rates by remoteness area were 
calculated by applying a correspondence from the 2011 SA2 to the 2011 RA. 
Socioeconomic status 
The Index of Relative Socio-economic Disadvantage (IRSD) is one of four Socio-Economic 
Indexes for Areas (SEIFAs) developed by the Australian Bureau of Statistics (ABS). This 
index is based on factors such as average household income, education levels and 
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unemployment rates. The IRSD is not a person-based measure; rather, it is an area-based 
measure of socioeconomic disadvantage in which small areas of Australia are classified on a 
continuum from disadvantaged to affluent. This information is used as a proxy for the 
socioeconomic disadvantage of people living in those areas and may not be correct for each 
person in that area. 
In this report, the first socioeconomic status group (quintile 1) corresponds to geographical 
areas containing the 20% of the population with the greatest socioeconomic disadvantage 
according to the IRSD (that is, the lowest socioeconomic group), and the fifth group 
(quintile 5) corresponds to the 20% of the population with the least socioeconomic 
disadvantage (that is, the highest socioeconomic group). 
Socioeconomic status for participation calculations  
For participation, women were allocated to a socioeconomic status using their residential 
postcode supplied at the time of screening. Caution is required when examining differences 
across socioeconomic status for several reasons. First, postcodes used to allocate women may 
not represent their location of residence. Second, because these are based on the 2011 Census, 
the accuracy of socioeconomic status classifications diminishes due to subsequent changes in 
demographics. Third, many postcodes (and hence women) are unable to be allocated to a 
socioeconomic status group. 
Socioeconomics status for incidence and mortality calculations 
Socioeconomic status quintiles were assigned to cancer cases according to the IRSD of the 
Statistical Local Area (SLA) of residence at the time of diagnosis, and to deaths according to 
the Statistical Area Level 2 (SA2) of residence at the time of death. 
Classification of invasive breast cancer and  
ductal carcinoma in situ 
Histology 
Invasive breast cancer 
Histology codes to classify invasive breast cancer into the groups that appear in Table 4.1 in 
this report were developed with the assistance of the State and Territory Cancer Registries. 
Groupings for invasive breast cancers are listed in Table E1. 
Table E1: Breast cancer by histology group 
Breast cancer group Type of breast cancer (ICD-O-3 codes) 
Invasive ductal carcinoma Pleomorphic carcinoma (8022) 
Carcinoma with osteoclast-like giant cells (8035) 
Basaloid carcinoma (8123) 
Scirrhous adenocarcinoma (8141) 
Carcinoma simplex (8231) 
Infiltrating duct carcinoma, not otherwise specified (8500) 
(continued) 
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Table E1 (continued): Breast cancer by histology group 
Breast cancer group Type of breast cancer (ICD-O-3 codes) 
 Duct carcinoma, desmoplastic type (8514) 
Infiltrating ductular carcinoma (8521) 
Infiltrating duct and lobular carcinoma (8522) 
Infiltrating duct mixed with other types of carcinoma (8523) 
Paget disease and infiltrating duct carcinoma of breast (8541) 
Paget disease and intraductal carcinoma of breast (8543) 
Invasive lobular carcinoma Pleomorphic lobular carcinoma, NOS (8519) 
Lobular carcinoma, not otherwise specified (8520) 
Infiltrating lobular mixed with other types of carcinoma (8524) 
Medullary carcinoma and atypical 
medullary carcinoma 
Medullary carcinoma, not otherwise specified (8510) 
Atypical medullary carcinoma (8513) 
Medullary carcinoma with lymphoid stroma (8512) 
Tubular carcinoma and invasive 
cribriform carcinoma 
Tubular adenocarcinoma (8211) 
Cribriform carcinoma, not otherwise specified (8201) 
Mucinous carcinoma Mucinous adenocarcinoma (8480) 
Mucin-producing adenocarcinoma (8481) 
Signet ring cell carcinoma (8490) 
Invasive papillary carcinoma Intraductal papillary adenocarcinoma with invasion (8503) 
Papillary adenocarcinoma, not otherwise specified (8260) 
Intracystic (papillary) adenocarcinoma (8504) 
Papillary carcinoma, not otherwise specified (8050) 
Solid papillary carcinoma (8509) 
Invasive micropapillary carcinoma (8507) 
Inflammatory carcinoma Inflammatory carcinoma (8530) 
Mesenchymal Sarcoma, NOS (8800) 
Spindle cell sarcoma (8801) 
Giant cell sarcoma (8802) 
Epithelioid sarcoma (8804) 
Undifferentiated sarcoma (8805) 
Fibrosarcoma (8810) 
Fibromyxosarcoma (8811) 
Low grade myofibroblastic sarcoma (8825) 
Malignant fibrous histiocytoma (8830) 
Liposarcoma, NOS (8850) 
Well differentiated liposarcoma, NOS (excluding superficial soft tissue) (8851) 
Myxoid liposarcoma (8852) 
Pleomorphic lipo sarcoma (8854) 
Leiomyo sarcoma (8890) 
Angiomyosarcoma (8894) 
(continued) 
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Table E1 (continued): Breast cancer by histology group 
Breast cancer group Type of breast cancer (ICD-O-3 codes) 
 Myosarcoma (8895) 
Rhabdomyo sarcoma (8900) 
Alveolar rhabdomyo sarcoma (8920) 
Stromal sarcoma, NOS (8935) 
Haemangio sarcoma (9120) 
Haemangio endothelioma, malignant (9130) 
Haemangiopericytoma, malignant (9150) 
Lymphangio sarcoma (9170) 
Osteosarcoma, NOS (9180 
Chondrosarcoma, NOS (9220 
Other—specified Metaplastic carcinoma, NOS(8575) 
Adenocarcinoma with squamous differentiation(8570) 
Adenocarcinoma with spindle cell metaplasia(8572) 
Squamous cell carcinoma, NOS(8070) 
Squamous cell carcinoma, keratinising, NOS(8071) 
Squamous cell carcinoma, large cell nonkeratinising, NOS(8072) 
Squamous cell carcinoma, spindle cell(8074) 
Spindle cell carcinoma, NOS(8032) 
Carcinosarcoma, NOS(8980) 
Adenocarcinoma with cartilaginous and osseous metaplasia(8571) 
Pseudosarcomatous carcinoma(8033) 
Malignant myoepithelioma(8982) 
Adenocarcinoma, NOS(8140) 
Phyllodes tumour, malignant(9020) 
Other—specified (continued) Paget disease, mammary(8540) 
Adenocarcinoma with apocrine metaplasia(8573) 
Apocrine adenocarcinoma(8401) 
Neuroendocrine carcinoma, NOS(8246) 
Small cell carcinoma, NOS(8041) 
Carcinoma with neuroendocrine differentiation(8574) 
Large cell neuroendocrine carcinoma(8013) 
Carcinoid , NOS(8240) 
Atypical carcinoid tumour(8249) 
Adenocarcinoma with mixed subtypes(8255) 
Mixed cell adenocarcinoma(8323) 
Secretory carcinoma of breast (C50._)(8502) 
Acinar cell carcinoma(8550) 
Mucoepidermoid carcinoma(8430) 
Lipid-rich carcinoma (C50._)(8314) 
(continued) 
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Table E1 (continued): Breast cancer by histology group 
Breast cancer group Type of breast cancer (ICD-O-3 codes) 
 Glycogen-rich carcinoma(8315) 
Clear cell adenocarcinoma, NOS(8310) 
Sebaceous carcinoma(8410) 
Mixed tumour, malignant(8940) 
Lymphoepithelial carcinoma(8082) 
Basal cell adenocarcinoma(8147) 
Trabecular carcinoma(8190   A) 
Solid carcinoma, NOS(8230) 
Adenomyoepithelioma, malignant(8983) 
Adenoid cystic carcinoma(8200) 
Epithelial-myoepithelial carcinoma(8562) 
Peripheral neuroectodermal tumour, NOS(9364) 
Granular cell tumour, malignant(9580) 
Adenosquamous carcinoma(8560) 
Comedocarcinoma, NOS (C50._)(8501) 
Unspecified Neoplasm, malignant(8000) 
Tumour cells, malignant(8001) 
Malignant tumour, spindle cell type(8004) 
Carcinoma, NOS(8010) 
Large cell carcinoma, NOS(8012) 
Carcinoma, undifferentiated(8020) 
Carcinoma, anaplastic(8021) 
Giant cell and spindle cell carcinoma(8030) 
Giant cell carcinoma(8031) 
Non-invasive 
Histology codes to classify non-invasive breast tumours were also developed with the 
assistance of the State and Territory Cancer Registries. Groupings for non-invasive breast 
tumours are listed in Table E2. Only the histology codes for DCIS are relevant to this report, 
as other non-invasive breast tumours have not been reported here. 
In interpreting incidence of non-invasive breast tumours, it should be noted that non-
invasive tumours that are diagnosed within four-months of an invasive breast cancer are 
excluded. This is referred to as the ‘four month rule’ and is based on the consensus view that 
in such a situation the invasive breast cancer was almost certainly present at the time of the 
DCIS diagnosis, but was not detected.  
The effect of applying this rule was the removal any non-invasive records in which an 
invasive breast cancer was diagnosed in less than or equal to 121 days of a non-invasive 
tumour.  
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Table E2: Non-invasive breast tumours by histology group 
Breast cancer group Type of breast cancer (ICD-O-3 codes) 
Ductal carcinoma in situ (DCIS) Papillary carcinoma in situ, NOS (8050) 
Cribriform carcinoma in situ (8201) 
Ductal carcinoma in situ, solid type (8230) 
Papillary adenocarcinoma, NOS, in situ (8260) 
Apocrine adenocarcinoma in situ (8401) 
Intraductal carcinoma, noninfiltrating, NOS (8500) 
Comedocarcinoma, non-infiltrating (8501) 
Secretory carcinoma of breast in situ (8502) 
Noninfiltrating intraductal papillary adenocarcinoma (8503) 
Noninfiltrating intracystic carcinoma (8504) 
Intraductal micropapillary carcinoma (8507) 
Cystic hypersecretory carcinoma in situ (8508) 
Solid papillary carcinoma in situ (8509) 
Noninfiltrating ductular carcinoma (8521) 
Intraductal carcinoma and lobular carcinoma in situ (8522) 
Ductal carcinoma in situ mixed with other types of carcinoma in situ (8523) 
Paget disease, in situ, and intraductal carcinoma of breast (8543) 
Lobular carcinoma in situ (LCIS) Pleomorphic lobular carcinoma in situ (8519) 
Lobular carcinoma in situ, NOS (8520) 
Other specified carcinoma in situ Squamous cell carcinoma in situ, NOS (8070) 
Adenocarcinoma in situ (8140) 
Mucinous adenocarcinoma in situ, NOS (8480) 
Paget disease, in situ, mammary (8540) 
Adenocarcinoma in situ with squamous metaplasia (8570) 
Unspecified Carcinoma in situ, NOS (8010) 
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Appendix F: Statistical methods 
Comparisons and tests of statistical significance 
This report includes statistical tests of the significance of comparisons of rates between 
population groups. Any statistical comparison applied to one variable must take account of 
any other potentially relevant variables. For example, any comparison of participation by 
state must also take account of differences in the distribution of age and sex between the 
states. These other variables are known as ‘confounding’ variables. 
Crude rates 
A ‘crude rate’ is defined as the number of events over a specified period of time (for 
example, a year) divided by the total population. For example, a crude cancer incidence rate 
is similarly defined as the number of new cases of cancer in a specified period of time 
divided by the population at risk. Crude mortality rates and cancer incidence rates are 
expressed in this report as number of deaths or new cases per 100,000 population. Crude 
participation rate is expressed as a percentage. 
Age-specific rates 
Age-specific rates provide information on the incidence of a particular event in an age group 
relative to the total number of people at risk of that event in the same age group. It is 
calculated by dividing the number of events occurring in each specified age group by the 
corresponding ‘at-risk’ population in the same age group and then multiplying the result by 
a constant (for example, 100,000) to derive the rate. Age-specific rates are often expressed per 
100,000 population. 
Age-standardised rates 
A crude rate provides information on the number of, for example, new cases of cancer or 
deaths from cancer in the population at risk in a specified period. No age adjustments are 
made when calculating a crude rate. Since the risk of cancer is heavily dependent on age, 
crude rates are not suitable for looking at trends or making comparisons across groups in 
cancer incidence and mortality. 
More meaningful comparisons can be made by the use of age-standardised rates, with such 
rates adjusted for age in order to facilitate comparisons between populations that have 
different age structures—for example, between Indigenous people and other Australians. 
This standardisation process effectively removes the influence of age structure on the 
summary rate. 
There are 2 methods commonly used to adjust for age: direct and indirect standardisation. In 
this report, the direct standardisation approach presented by Jensen and colleagues (1991) is 
used. To age-standardise using the direct method, the first step is to obtain population 
numbers and numbers of cases (or deaths) in age ranges, typically 5-year age ranges. The 
next step is to multiply the age-specific population numbers for the standard population (in 
this case, the Australian population as at 30 June 2001) by the age-specific incidence rates (or 
death rates) for the population of interest (such as those in a certain socioeconomic status 
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group or those who lived in Major cities). The next step is to sum across the age groups and 
divide this sum by the total of the standard population to give an age-standardised rate for 
the population of interest. Finally, this is expressed per 1,000 or 100,000 as appropriate. 
Confidence intervals 
Population numbers for incidence and mortality and screening have a natural level of 
variability for a single year above and below what might be expected in the mean over many 
years. The percentage variability is small for large population numbers but high for small 
numbers such as mortality in a young age group. One measure of the likely difference is that 
of standard error, which indicates the extent to which a population number might have 
varied by chance in only 1 year of data. In the 95% confidence interval, there are about 19 
chances in 20 that the difference will be less than 2 standard errors. 
There are several methods for calculating confidence intervals. The 95% confidence intervals 
(CIs) in this report were calculated using a method developed by Dobson and others (1991). 
This method calculates approximate confidence intervals for a weighted sum of Poisson 
parameters. 
Interpretation of confidence intervals 
Some indicators have a 95% confidence interval presented along with the rates. This is 
because the observed value of a rate may vary due to chance, even where there is no 
variation in the underlying value of the rate. The 95% confidence interval represents a range 
(interval) over which variation in the observed rate is consistent with this chance variation. 
In other words, there is a 95% confidence that the true value of the rate is somewhere within 
this range. 
These confidence intervals can be used as a guide to whether differences in a particular rate 
are consistent with chance variation. Where the confidence intervals do not overlap, the 
difference between rates is greater than that which could be explained by chance, and is 
regarded as statistically significant. 
It is important to note that the overlapping of confidence intervals does not imply that the 
difference between 2 rates is definitely due to chance. Instead, an overlapping confidence 
interval represents a difference in rates that is too small to allow differentiation between a 
real difference and one that is due to chance variation. It can therefore only be stated that no 
statistically significant differences were found, and not that no differences exist. 
The approximate comparisons presented might understate the statistical significance of some 
differences, but they are sufficiently accurate for the purposes of this report. 
As with all statistical comparisons, care should be exercised in interpreting the results of the 
comparison. If 2 rates are statistically significantly different from each other, this means that 
the difference is unlikely to have arisen by chance. Judgment should, however, be exercised 
in deciding whether or not the difference is of any clinical significance. 
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Glossary 
Aboriginal or Torres Strait Islander: A person of Aboriginal and/or Torres Strait Islander 
descent who identifies as an Aboriginal and/or Torres Strait Islander. See also Indigenous. 
age-specific rate: A rate for a specific age group. The numerator and denominator relate to 
the same age group. 
age-standardised rate: A method of removing the influence of age when comparing 
populations with different age structures. This is usually necessary because the rates of many 
diseases vary strongly (usually increase) with age. The age structures of the different 
populations are converted to the same ‘standard’ structure, which allows comparison of 
disease rates.  
Australian Statistical Geography Standard (ASGS): Common framework defined by the 
Australian Bureau of Statistics for collection and dissemination of geographically classified 
statistics. The ASGS replaced the Australian Standard Geographical Classification (ASGC) in 
July 2011. 
assessment: Further investigation of a mammographic abnormality or symptom reported at 
screening.  
benign: Not malignant. 
biopsy: Small sample of tissue that is taken to obtain a definitive diagnosis of an 
abnormality. 
cancer (malignant neoplasm): A large range of diseases in which some of the body’s cells 
become defective, and begin to multiply out of control. These cells can invade and damage 
the area around them, and can also spread to other parts of the body to cause further 
damage. 
cancer death: A death where the underlying cause of death is indicated as cancer. People 
with cancer who die of other causes are not counted in the mortality statistics in this 
publication. 
confidence interval: A range determined by variability in data, within which there is a 
specified (usually 95%) chance that the true value of a calculated parameter lies. 
ductal carcinoma in situ: A non-invasive tumour of the mammary gland (breast) arising 
from cells lining the ducts. 
false negative: A test that has incorrectly observed that the disease is not present. 
false positive: A test that has incorrectly observed that the disease is present. 
first screening round: See screening round. 
Indigenous: A person of Aboriginal and/or Torres Strait Islander descent who identifies as 
an Aboriginal and/or Torres Strait Islander. See also Aboriginal or Torres Strait Islander. 
in situ: A Latin term meaning in place or position; undisturbed. 
incidence: The number of new cases (for example, of an illness or event) occurring during a 
given period, usually 1 year. 
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index screening year: The year for which an interval cancer rate and program sensitivity 
rate are determined. 
index screens: All screening examinations performed within the index screening year. 
interval cancer (invasive) (as defined for national reporting purposes by Kavanagh et al. 
1999, with minor changes endorsed by the then-named National Advisory Committee): 
• an invasive breast cancer diagnosed after completion of a negative screening episode 
and before the next screening examination (within 24 months from the date of the 
previous screen) 
• a case of invasive breast cancer that is diagnosed at early review or in the interval 
between assessment and early review, where the recommendation for early review is 
6 months or more from the screening date 
• breast cancer diagnosed in a woman by BreastScreen Australia within 24 months of a 
negative screen (early rescreen) if the woman presents with a breast lump and/or clear 
or bloodstained nipple discharge in the breast in which the breast cancer was diagnosed 
• an invasive breast cancer diagnosed between 6 and 24 months after a recommendation 
for assessment is made and a woman fails to attend assessment. 
invasive cancer: A tumour whose cells have the potential to spread to nearby healthy or 
normal tissue or to more distant parts of the body. 
malignant: Abnormalities in cells or tissues consistent with cancer. 
mammogram: A radiographic depiction of the breast. 
metastasis: The process by which cancerous cells are transferred from one part of the body to 
another; for example, via the lymphatic system or the bloodstream. 
morbidity: Illness. 
mortality: The number of deaths occurring during a given period. 
new cancer case: A person who has a new cancer diagnosed for the first time. One person 
may have more than once cancer and therefore may be counted twice in incidence statistics 
if it is decided that the 2 cancers are not of the same origin. This decision is based on a series 
of principles set out in more detail in a publication by Jensen et al. (1991). 
rescreening: The next screening examination after the screening episode in the index 
screening year. 
risk factor: An attribute or exposure that is associated with an increased probability of a 
specified outcome, such as the occurrence of a disease. Risk factors are not necessarily the 
causes of disease. 
screening: The performance of tests on apparently well people in order to detect a medical 
condition at an earlier stage than would otherwise be the case. 
screening episode: All attendances for screening and assessment within 6 months relating to 
a particular round of screening. It starts at the date of attendance for screening. It is 
completed when: 
• a recommendation is made to return the woman to routine rescreening 
• a recommendation is made for early review at 6 months or more from the screening date 
• a diagnosis of cancer is made 
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• the woman fails to attend for technical recall or assessment within 6 months 
• the woman dies. 
screening round: The first screening round is a woman’s first visit to a mammography 
screening service; a subsequent screening round means that she has been screened before. 
For example, if she attends for a fourth screening round, she has been screened three times 
before. 
significant difference: Where rates are referred to as significantly different, or one rate is 
deemed significantly higher or lower than another, these differences are statistically 
significant. Rates are deemed statistically significantly different when their confidence 
intervals do not overlap, since their difference is greater than what could be explained by 
chance. See ‘confidence intervals’ in Appendix F for more information. 
symptom: Any evidence of disease apparent to the patient. For the purposes of this report, 
symptoms refer to a self-reported breast lump and/or bloodstained or watery nipple 
discharge. 
target population: Women aged 50–69. 
tumour: An abnormal growth of tissue. Can be benign (not a cancer) or malignant (cancer).  
the Institute: The Australian Institute of Health and Welfare. 
ultrasound: Diagnostic method based on the reflection of ultrasonic sound waves generated 
through scanning of, in this case, the breast. The reflections are viewed on a computer screen 
or photograph, and checked for variations in images. 
underlying cause of death: The condition, disease or injury initiating the sequence of events 
leading directly to death; that is, the primary, chief or principal cause.  
women-years: The denominator for the interval cancer rate, it is the ‘number of years at risk’ 
of being diagnosed with an interval cancer, and takes into account women who screen 
annually rather than every 2 years (who would be at risk for the first year after their screen 
but not the second). 
Note: Terms in bold are defined elsewhere in the glossary. 
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Supplementary online data tables 
Additional tables are available as online Excel tables at <www.aihw.gov.au>, under the 
‘Additional material’ tab for this report. These tables contain detailed statistics for many of 
the tables and figures presented in summary form in both the body of the report and in 
Appendix A. Supplementary data tables have the prefix ‘S’ (for example, ‘Table S1.1’). 
There are 7 Excel files, one for each performance indicator: 
• Indicator 1 Participation 
• Indicator 2 Rescreening 
• Indicator 3 Recall to assessment 
• Indicator 4 Invasive breast cancer detection 
• Indicator 5 DCIS detection 
• Indicator 6 Sensitivity 
• Indicator 7 Incidence 
• Indicator 8 Mortality 
BreastScreen Australia 
monitoring report 2012–2013
The BreastScreen Australia monitoring report 2012–2013 presents the latest 
national statistics in the monitoring of BreastScreen Australia, which aims 
to reduce illness and death resulting from breast cancer through organised 
screening to detect cases of unsuspected breast cancer in women, thus 
enabling early intervention. Around 55% of women in the target age 
group 50–69 took part in the program, with more than 1.4 million women 
screening in 2012–2013.
Breast cancer mortality in 2012 was 44 deaths per 100,000 women.
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